AU745815B2 - Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using - Google Patents

Description

1-

AUSTRALIA

PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT O R IGI NA L Name of Applicant/s: Actual lnventor/s: Address for Service: Invention Title: Amgen Inc.

Charles F. Morris and William C. Kenney and Bao-Lu Chen and Sharon L. Aukerman and Glenn F. Pierce and Eric W. Hsu BALDWIN SHELSTON WATER MARGARET STREET

CZ

SYDNEY NSW 2000 U- 'ANALOGS OF KERATINOCYTE GROWTH FACTOl? NiLC 4cJOS ~CNCDINOI S"JCH ANLK, Pkcccscc OF N1A'KiNCI A-Dt mupoDC !J&INpI Details of Original Application No. 37077/95 dated 12 OCT 1995 The following statement is a full description of this invention, including the best method of performing it known to me/us:- File: 22135.00 -la- ANALOGS OF KERATINOCYTE GROWTH FACTOR, NUCLEIC ACIDS ENCODING SUCH ANALOGS, PROCESSES OF MAKING AND METHODS OF USING Field of the Invention The present invention relates to recombinant DNA technology and protein engineering. Specifically, recombinant DNA methodologies have been applied to generate polypeptide analogs of keratinocyte growth factor (KGF), a potent mitogen of non-fibroblast epithelial cell cell growth, wherein the analogs have improved stability as 10 compared to that of the parent KGF.

o Background of the Invention Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

15 The complex process of tissue generation and regeneration is mediated by a number of protein factors sometimes referred to as soft tissue growth factors. These molecules are generally released by one cell type and act to influence proliferation of other cell types. (Rubin et al. (1989), Proc. Nat'l. Acad. Sci. USA, 86:802-806). Some soft tissue growth factors are secreted by particular cell types and influence the proliferation, differentiation, and/or maturation of responsive cells in the development of multicellular organisms (Finch et al. (1989), Science, 245:752-755). In addition to their roles in developing organisms, some are significant in the continued health and lbmaintenance of more mature systems. For instance, in mammals, there are many systems where rapid cell turnover occurs. Such systems include the skin and the gastrointestinal tract, both of which are comprised of epithelial cells. Included within this group of soft tissue growth factors is a protein family of fibroblast growth factors (FGFs).

There are currently eight known FGF family members which share a relatedness among primary r r r r F1 ~22135-OO.DOC 2 structures: basic fibroblast growth factor, bFGF (Abraham et al. (1986), EMBO 5:2523-2528); acidic fibroblast growth factor, aFGF (Jaye et al. (1986), Science, 231:541-545); int-2 gene product, int-2 (Dickson Peters (1987), Nature, 312:833); hst/kFGF (Delli-Bovi et al. (1987), Cell, 50:729-737) and Yoshida et al. (1987), Proc. Natl. Acad. Sci. USA, 84:7305- 7309); FGF-5 (Zhan et al. (1988), Mol. Cell. Biol., 8:3487-3495); FGF-6 (Marics et al. (1989), Oncogene, 10 A:335-340); keratinocyte growth factor (Finch et al.

(1989), Science, 21:752-755); and hisactophilin (Habazzettl et al. (1992), Nature, 32.:855-858).

Among the FGF family of proteins, keratinocyte growth factor is a unique effector of nonfibroblast epithelial (particularly keratinocyte) cell proliferation derived from mesenchymal tissues. The term "native KGF" refers to a natural human (hKGF) or recombinant (rKGF) polypeptide (with or without a signal sequence) as depicted by the amino acid sequence presented in SEQ ID NO:2 or an allelic variant thereof.

(Unless otherwise indicated, amino acid numbering for molecules described herein shall correspond to that presented for the mature form of the native molecule minus the signal sequence), as depicted by amino acids 32 to 194 of SEQ ID NO:2.] Native KGF may be isolated from natural human sources (hKGF) or produced by recombinant DNA techniques (rKGF) (Finch et al. (1989), supra; Rubin et al. (1989), supra; Ron et al. (1993), The Journal of Biological Chemistry, 26814):2984- 2 9 8 8 and Yan et al. (1991), In Vitro Cell. Dev. Biol., 22A:437-438).

It is known that native KGF is relatively unstable in the aqueous state and that it undergoes chemical and physical degradation resulting in a loss of biological activity during processing and storage (Chen et al.(1994), Pharmaceutical Research, 11:1582- -3- 1589). Native KGF is prone also to aggregation at elevated temperatures and it becomes inactivated under acidic conditions (Rubin et al. (1989), Proc. Nat1.

Acad. Sci. USA, 86:802-806). Aggregation of native

KGF

in aqueous solution also results in inactivated protein.

This is disadvantageous because such loss of activity makes it impractical to store aqueous formulations of native KGF proteins for extended periods of time or to administer the protein over extended periods. Moreover, 10 this is Particularly problematic when preparing pharmaceutical formulations, because aggregated proteins have been known to be immunogenic (Cleland et al. (1993), Crit. Rev. Therapeutic Drug Carrier Systems, 1&:307-377; Robbins et al. (1987), Diabete, U:838-845; and Pinckard et al. (1967), Clin. Exp. Imunol., 2:331- 340).

Native KGF comprises five cysteine residues, namely amino acids 1, 15, 40, 102, and 106 (Finch et al.

(1989), Science, 2A:752-755). Although the cysteine content of native KGF was reported, what has not been reported are the roles played by cysteine residues with :respect to activity essentiality to biological activity) and tertiary structure proclivity to form undesirable intermolecular or intramolecular disulfide bonds). Thus, there is no prior art teaching of which, if any, cysteine residues are essential or are involved in undesirable disulfide bond formation, making the protein susceptible to aggregation and/or instability.

In order to attempt to improve or otherwise alter one or more of the characteristics of native

KGF,

protein engineering may be employed. Recombinant

DNA

technology has been utilized to modify the sequences of native

KGF.

Ron et al. (1993), J. Biol. Chem., 268(4):2984-2988 reported modified KGF polypeptides 4 having 3, 8, 27, 38 or 49 amino acids deleted from the N-terminus. Those polypeptides missing 3, 8, or 27 N-terminal residues retained heparin binding ability; the others did not. Also, the polypeptides missing 3 and 8 residues were reported as being fully active, whereas the form missing 27 residues was 10-20 fold less mitogenic, and the forms lacking 38 or 49 amino acids did not have mitogenic: activity. The stability of the modified KGF polypeptides was not discussed or otherwise reported.

Published PCT application no. 90/08771, supra, also reported the production of a chimeric protein 2.wherein about the first 40 N-terminal amino acids of the .:mature form of native KGF were combined with the Cterminal portion (about 140 amino acids) of aFGF. The chimera was reported to target keratinocytes like

KGF,

but it lacked susceptibility to heparin, a characteristic of aFGF but not KGF. The stability of the chimera was not discussed or otherwise reported.

Thus, the literature has not reported a modified KGF molecule having significantly improved stability relative tonative KGF. Moreover, the literature has not reported sufficient teachings or evidence to provide a reasonable expectation of successfully generating KGF molecules with such desirable characteristics.

Generally, the effects upon biological activity of any amino acid change upon a protein will vary depending upon a number of factors, including the three-dimensional structure of the protein and whether or not the modifications are to the receptor binding region of the primary sequence of the protein. As neither the three-dimensional structure nor the receptor binding region on the primary structure of native

KGF

has been published, the knowledge within the art does not permit generalization about the effects of amino acid modifications to native KGF based upon the effects of amino acid modifications on even commonly categorized proteins.

This invention relates to polypeptide molecules encoding such analogs that exhibit enhanced stability when subjected to typical pH, thermal and/or other storage conditions) as compared to native KGF.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

Summary of the Invention The present invention provides novel, biologically active polypeptide analogs of 10 KGF. For purposes of this invention, the term "KGF" includes native KGF and proteins characterized by a peptide sequence substantially the same as the peptide sequence of native KGF which retains cysteine residues corresponding to Cys' and Cys" 5 of native KGF (Cys 32 and Cys 46 of SEQ ID NO:2) and which retains some or all of the biological activity of native KGF, particularly non-fibroblast epithelial cell proliferation. [When 0 15 making reference to Figures 4, 7-24 and 37-50 and the specific amino acid position, the initial methionine in the sequence should be considered residue number By "characterized by a peptide sequence substantially the same as the peptide sequence of native KGF" is meant a peptide sequence which is encoded by a DNA sequence capable of hybridizing to nucleotides 201 to 684 of SEQ ID NO:1, preferably under stringent hybridization conditions.

6' c ^sQ-Z-i/ The determination of a corresponding amino acid position between two amino acid sequences may be determined by aligning the two sequences to maximize matches of residues including shifting the amino and/or carboxyl terminus, introducing gaps as required and/or deleting residues present as inserts in the candidate. Database searches, sequences analysis and manipulations may be performed using one of the well-known and routinely used sequence homology/identity scanning e O oo ole°° o °o/ o o* fo~ 6 algorithm programs Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U5:2444-2448; Altschul ec al. (1990), J. Mol. Biol., 211:403-410; Lipman and Pearson (1985), Science, 22:1435 or Devereux et al.

(1984), Nuc. Acids Res., 12:387-395).

Stringent conditions, in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents and other parameters typically controlled in hybridization reactions.

Exemplary stringent hybridization conditions are hybridization in 4 X SSC at 62-67° followed by washing in 0.1 X SSC at 62-67* C. for approximately an hour. Alternatively, exemplary stringent hybridization conditions are hybridization in 45-55% foriamide, 4 X SSC at 40-45 0 C. [See, T. Maniatis et. al., Molecular Cloning (A Laboratory Manual); Cold Spring Harbor Laboratory (1982), pages 387 to 389].

Thus, the proteins include allelic variations, or deletion(s), substitution(s) or insertion(s) of amino acids, including fragments, chimeric or hybrid molecules of native KGF. One example of KGF includes chargechange polypeptides wherein one-or more of amino acid residues 41-154 of native KGF (preferably residues Arg 4 1 Gin 43 Lys 55 Lys 95 Lys 128 Asn 137 Gln 138 Lys 139 Arg144, Lys 147 Gln 152 Lys 153 or Thr154) are deleted or substituted with a neutral residue or negatively charged residue selected to effect a protein with a reduced positive charge (as taught in WO 96/11952), specifically including R(144)Q, a KGF'having a substitution of glutamine for arginine at amino acid positions 144 of native KGF. Another example of KGF includes proteins generated by substituting at least one amino acid having a higher loop-forming potential for at least one amino acid within a loop-forming region of Asn115-His11 6 Tyr117-Asn118-Thr19 of native KGF (as taught in WO 96/11952) 7 specifically including H(116)G, a KGF having a substitution of glycine for histidine at amino acid position 116 of native KGF. A still further example includes proteins having one or more amino acid substitutions, deletions or additions within a region of 123-133 (amino acids 154-164 of SEQ ID NO:2) of native KGF; these proteins may have agonistic or antagonistic activity.

10 Surprisingly, it has been discovered when a KGF molecule parent molecule) having cysteine residues corresponding (as determined using techniques described above) to Cys 1 and Cys 15 of native KGF (cysteine residues 32 and 46 of SEQ ID N0:2) is modified by replacing the corresponding cysteines, the resultant .KGF analog has improved stability as compared to the parent molecule. Preferably, in addition to having increased stability, the invention is directed to those analogs which also exhibit full biological activity at least substantially similar receptor binding or affinity) as compared to native KGF.

In another aspect of the invention, purified and isolated nucleic acid molecules encoding the various biologically active polypeptide analogs of KGF are described. In one embodiment, such nucleic acids comprise DNA molecules cloned into biologically functional plasmid or viral vectors. In another embodiment, nucleic acid constructs may then be utilized to stably transform a procaryotic or eucaryotic host cell. In still another embodiment, the invention involves a process wherein either a procaryotic (preferably E. coli) or eucaryotic host cell stably transformed with a nucleic acid molecule is grown under suitable nutrient conditions in a manner allowing the expression of the KGF analog. Following expression, the -8resultant recombinant polypeptide can be isolated and purified.

A further aspect of the invention concerns pharmaceutical formulations comprising a therapeutically effective amount of a KGF analog and an acceptable pharmaceutical carrier. Such formulations will be useful in treating patients afflicted with epithelial diseases and injuries.

In this vein, another aspect relates to methods of stimulating epithelial cell growth by administering to a patient a therapeutically effective amount of a KGF analog. In one embodiment, non-fibroblast epithelial cells are the cells whose proliferation is stimulated. Such epithelial cells include various adnexal cells, pancreatic cells, liver 10 cells, and mucosal epithelium in the respiratory and gastrointestinal tracts.

S* According to a first aspect, the present invention provides a biologically active analog of native keratinocyte growth factor (KGF), said native KGF having the amino 0 acid sequence of SEQ ID NO.2, wherein the analog comprises a modificati6n of at least the cysteine at position 32 and the cysteine at position 46 of the amino acid sequence of 00 the native KGF, which modification is either a deletion or substitution, with the proviso that: the analog is not a KGF comprising a deletion of amino acids 1 to 58 of the native KGF; and the analog is not a KGF protein consisting of amino acids 55 to 194 of the native KGF.

According to a second aspect, the present invention provides an analog of native keratinocyte growth factor (which corresponds to amino acids 32-194 of SEQ ID NO:2, with or without a signal sequence), termed "KGF", wherein said analog is AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue and wherein the analog is covalently attached to a chemical moiety.

In one embodiment; the initial methionine residue of SEQ ID NO:58 is absent.

-9- According to a third aspect, the present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of an analog of KGF according to the first or second aspect and a pharmaceutically acceptable carrier.

According to a fourth aspect, the present invention provides a recombinant nucleic acid molecule encoding an analog according to the first aspect.

According to a fifth aspect, the present invention provides a biologically functional vector comprising a nucleic acid molecule according to the fourth aspect.

According to a sixth aspect, the present invention provides a prokaryotic or i eukaryotic host cell containing a nucleic acid molecule according to the fourth aspect or a biologically functional vector according to the fifth aspect.

According to a seventh aspect, the present invention provides a nucleic acid molecule which is SEQ ID NO:57.

According to an eighth aspect, the present invention provides a process for the production of an analog of KGF, the process comprising growing under suitable nutrient S 15 conditions a host cell according to the sixth aspect in a manner allowing expression of the encoded analog, and isolating the analog so produced.

According to a ninth aspect,the present invention provides a use of an effective amount of the analog of KGF according to the first or second aspect for the production of a medicament for stimulating production of non-fibroblast epithelial cells.

According to a tenth aspect, the present invention provides a use of an effective amount of the analog of KGF according to the first or second aspect for the production of a medicament for stimulating production ofnon-fibroblast epithelial cells in a patient for the prevention or treatment of a condition, wherein said condition is selected from bums and other partial and full-thickness injuries; epidermolysis bullosa; chemotherapy- 1 induced alopecia; male-pattern baldness; progressive loss of hair in men and women; 22135-00.DOC -9agastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; coreal abrasion; progressive gum disease; ear drum damage or diabetes mellitus.

According to an eleventh aspect, the present invention provides a method of stimulating the production of non-fibroblast epithelial cells comprising the administration to a subject of an effective amount of an analog of KGF according to the first or second aspect, or a pharmaceutical composition according to the third aspect.

10 According to a twelfth aspect, the present invention provides a method for the prevention or treatment of a condition in a patient comprising the administration of an effective amount of an analog of KGF according to the first or second aspect, or a *o S pharmaceutical formulation according to the third aspect, wherein said patient has a condition selected from bums and other partial and full-thickness injuries; epidermolysis 15 bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; comeal abrasion; progressive gum disease; ear drum damage or diabetes mellitus.

According to a thirteenth aspect, the present invention provides a use of an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue for the production of a medicament for cO 22135-.DOC OF\ 22135-00.DOC -9b stimulating production of non-fibroblast epithelial cells in a patient in need thereof, i wherein the non-fibroblast epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells.

According to a fourteenth aspect, the present invention provides a method of stimulating the production of non-fibroblast epithelial cells comprising the administration to a subject of an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue or a pharmaceutical composition thereof, wherein the non-fibroblast epithelial cells are 10 selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells.

0 According to a fifteenth aspect, the present invention provides a use of an \effective amount ofAN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue for the production of a medicament for 15 stimulating production of non-fibroblast epithelial cells in a patient for the prevention or treatment of a condition, wherein said condition is selected from bums and other partial and futl-thickness injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; progressive gum disease; ear drum damage or diabetes mellitus.

According to a sixteenth aspect, the present invention provides a method for the S 25- prevention or treatment of a condition in a patient comprising the administration of an OFF\ 2135-.D we 22135-O.DOC 9c effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue wherein said patient has a condition selected from bums and other partial and full-thickness injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; progressive gum disease; ear drum damage or diabetes mellitus.

10 According to a seventeenth aspect, the present invention provides a method of stimulating the production ofnon-fibroblast epithelial cells comprising contacting said cells with an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue or a pharmaceutical composition thereof, wherein the non-fibroblast epithelial cells are selected from adnexal 15 structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells.

In one embodiment of the thirteenth to seventeenth aspects, the initial methionine residue of SEQ ID NO:58 is absent.

According to an eighteenth aspect, the present invention provides a kit comprising an analog ofKGF according to the first or second aspect, or a pharmaceutical formulation according to the third aspect.

According to a nineteenth aspect, the present invention provides a method of stimulating the production of non-fibroblast epithelial cells comprising contacting said cells with an effective amount of an analog of KGF according to the first or second zff aspect, or a pharmaceutical composition according to the third aspect.

22135-00.DOC 9d- Unless the context clearly requires otherwise, throughout the description and the Claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

Brief Description of the Figures Figures 1A and 1B show the nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of native KGF (the nucleotides encoding the mature form of native KGF is depicted by bases 201 to 684 of SEQ ID NO:1 and the mature form of KGF is depicted by amino acid residues 32 to 194 of SEQ ID NO:2).

Figures 2A, 2B and 2C show the plasmid maps of pCFM1156, pCFM1656 and S*o pCFM3102, respectively.

Figure 3 shows the nucleotide (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences of the construct RSH-KGF.

Figure 4 shows the nucleotide (SEQ ID NO:5) and amino acids (SEQ ID NO:6) 15 sequences of the construct contained in plasmid KGF.

Figure 5 shows the chemically synthesized OLIGOs (OLIGO#6 through OLIGO#11; SEQ ID NO:12-17, respectively) used to substitute the DNA sequence between a KpnI site and EcoRI site (from amino acid positions 46 to 85 of SEQ ID No:6) in the construct contained in plasmid KGF to produce the construct in plasmid KGF (dsd).

Figure 6 shows the chemically synthesized OLGIOs (OLIGO#12 through OLIGO#24; SEQ ID NO: 18-30, respectively) used to construct KGF (codon optimized).

2I1S-00 DOC -9e Figure 7 shows the nucleotide (SEQ ID NO:31) and amino acid (SEQ ID NO:32) sequences of C(1,15)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 of native KGF.

Figure 8 shows the nucleotide (SEQ ID NO:33) and amino acid (SEQ ID NO:34) sequences of AN3/C(15)S, a KGF analog having a deletion of the first 3 amino acids of the N-terminus and a substitution of serine for cysteine at amino acid position 15 of native KGF.

S S 22135-OO.DOC 10 Figure 9 shows the nucleotide (SEQ ID and amino acid (SEQ ID NO:36) sequences of N3/(15) KGF analog having a deletion of the first 3 amino acids of the N-terminus and a deletion of cysteine at amino acid position 15 of native KGF.

Figure 10 shows the nucleotide (SEQ ID NO:37) and amino acid (SEQ ID NO:38) sequences of AN8/C(15)S K G F an a l o g h a i n go a 'f a 1 5 a KGF analog having a deletion of the first 8 amino acids o 1 f the N-terminus and a substitution of serine for 10 cysteine at amino acid position 15 of native

KGF.

Figure 11 shows the nucleotide (SEQ ID NO:39) and amino acid (SEQ ID NO:40) sequences of AN8/C(15)-, a KGF analog having a deletion of the first 8 amino acids of the N-terminus and a deletion of cysteine at amino 15 acid position 15 of native

KGF.

Figure 12 shows the nucleotide (SEQ ID NO:41) and amino acid (SEQ ID NO:42) sequences of AN15, a KGF analog having a deletion of the first 15 amino acids of the N-terminus of native

KGF.

0 Figure 13 shows the nucleotide (SEQ ID NO:43) :and amino acid (SEQ ID NO:44) sequences of AN16, a KGF analog having a deletion of the first 16 amino acids of the N-terminus of native

KGF.

Figure 14 shows the nucleotide (SEQ ID and amino acid (SEQ ID NO:46) sequences of AN17, a KGF analog having a deletion of the first 17 amino acids of the N-terminus of native

KGF.

Figure 15 shows the nucleotide (SEQ ID NO:47) and amino acid (SEQ ID NO:48) sequences of AN18, a KGF analog having a deletion of the first 18 amino acids of the N-terminus of native

KGF.

Figure 16 shows the nucleotide (SEQ ID NO:49) and amino acid (SEQ ID NO:50) sequences of AN19, a KGF analog having a deletion of the first 19 amino acids of the N-terminus of native

KGF.

11 Figure 17 shows the nucleotide (SEQ ID NO:51) and amino acid (SEQ ID NO:52) sequences of AN20, a KGF analog having a deletion of the first 20 amino acids of the N-terminus of native

KGF.

Figure 18 shows the nucleotide (SEQ ID NO:53) and amino acid (SEQ ID NO:54) sequences of AN21, a KGF analog having a deletion of the first 21.amino acids of the N-terminus of native

KGF.

Figure 19 shows the nucleotide (SEQ ID "10 and amino acid (SEQ ID NO:56) sequences of AN22, a KGF analog having a deletion of the first 22 amino acids of the N-terminus of native KGF.

:Figure 20 shows the nucleotide (SEQ ID NO:57) and amino acid (SEQ ID NO:58) sequences of AN23, a KGF 15 analog having a deletion of the first 23 amino acids of the N-terminus of native KGF.

Figure 21 shows the nucleotide (SEQ ID NO:59) and amino acid (SEQ ID NO:60) sequences of AN24, a KGF analog having a deletion of the first 24 amino acids of the N-terminus of native

KGF.

Figure 22 shows the nucleotide (SEQ ID NO:61) and amino acid sequences (SEQ ID NO:62) of C(1,15)S/R(144)E, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 and a substitution of glutamic acid for arginine at amino acid position 144 of native

KGF.

Figure 23 shows the nucleotide (SEQ ID NO:63) and amino acid (SEQ ID NO:64) sequences of C(1,15)S/R(144)Q, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 and a substitution of glutamine for arginine at amino acid position 144 of native KGF.

Figure 24 shows the nucleotide (SEQ ID and amino acid (SEQ ID NO:66) sequences of AN23/R(144)Q, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine 12for arginine at amino acid position 144 of native KGF.

Figure 25 shows the amount of remaining soluble protein when native KGF and C(1,15)S were stored in 20 mM Na phosphate, 0.15 M NaC1, pH 7.0 at 37 0 C for 27 hrs.

Figure 26 shows the amount of remaining soluble protein, when native KGF, AN15 and C(1,15)S were stored in 50 mM NaPO 4 0.15 M NaC1, pH 7.0 at 37 0 C for 27 hrs.

Figure 27 shows the amount of soluble protein, of native KGF, C(1,15)S, C(1,15)S/R(144)E and C(1,15)S/R(144)Q determined by size exclusion HPLC, as a function of incubation time at 37 0

C.

Figure 28 shows the estimated melting temperature as a function of pH for o native KGF, C(1,15)S, C(1,15)S/R(144)Q and C(1,15)S/R(144)E.

Figure 29 shows a typical profile of mitogenic activity of C(1,15)S determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis by comparing it :to a native KGF standard curve.

S 15 Figure 30 shows a typical profile of the mitogenic activity of AN15 determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 31 shows a typical profile of mitogenic activity of AN23 determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 32 shows a typical profile of the mitogenic activity of AN23/R(144)Q determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

22135-00.DOC -13- Figure 33 shows a typical profile of the mitogenic activity of C(1,15)S/R(144)Q determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 34 shows a typical profile of the mitogenic activity of C(1,15)S/R(144)E determined by measuring the incorporation of 3 H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 35 shows the effects of native KGF, KGF-a, AN15, C(1,15)S and AN23 on serum chemistries.

o.

:Figure 36 shows the nucleotide (SEQ ID NO:77) and amino acid (SEQ ID NO:78)

C

sequences of C(1,15,40)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15 and 40 of native KGF.

Figure 37 shows the nucleotide (SEQ ID NO:79) and amino acid (SEQ ID sequences of C(1,15,102)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15 and 102 of native KGF.

15 Figure 38 shows the nucleotide (SEQ ID NO: 81) and amino acid (SEQ ID NO:82) oC sequences of C(1,15,102,106)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15, 102 and 106 of native KGF.

Figure 39 shows the nucleotide (SEQ ID NO:83) and amino acid (SEQ ID NO:84) sequences of AN23/N(137)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for asparagine at amino acid position 137 of native KGF.

Figure 40 shows the nucleotide (SEQ ID NO:85) and amino acid (SEQ ID NO:86) sequences of AN23/K(139)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic 22135-00.DOC 14 acid for lysine at amino acid position 139 of native

KG?.

Figure 41 shows the nucleotide (SEQ ID NO:87) and amino acid (SEQ =D NO:88) sduences of AN23/X(l39)Q, a KG? analog having a deletion of the f irst 23 amino acids of the N-terminus and a substitution of glutamine for lysine at amino acid position 139- of native KG?.

Figure 42 shows-the nucleotide (SEQ ID NO:89) and amino acid (SEQ ID NO:90) sequences of WN23/R(144)A, a KG? analog having a deletion of the first 23 amn acids of the N-terminus and a substitution of alanine :9:..for arginine at amino acid position. 144 of native KG?.

Figure 43 shows the nucleotide (SEQ ID NO:91) and amino acid (SEQ ID NO:92) sequences of*AN23/R(144)E, is. 1 a KG? analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for arginine at amino acid position 144 of native KcF.

S SFigure 4 4 shows the nucleotide (SEQ ID NO:93) and-amino acid (SEQ =D NO:94) sequences of AN23/R(I44)L.

a KG? analog having a deletion of the first 23 amn 5: acids of the N-termznus and a substitution of leucine for arginine at amino acid position 144 of native KG?.

Figure 45 Shows the nucleotide (SEQ and amino acid (SEQ ID NO:96) sequences of AN23/K(147)E, a KG? analog having a deletion of the first 23amn acids of the N-terminus and a substitution of glutamic acid for lysine at amino acid position 147 of native

KG?.

Figure 46 shows the nucleotide (SEQ ID NO:.97) and amino acid (SEQ ID N~O:98) sequences of AN23/K(147)Q, a KG? alog having- a deletion of the first 23amn acids of the N-terminus and a substitution of glutauifle for lysine at aioacid position 147 of native KG?.

Figure 47 shows the nuCleotida. (SEQ ID NO:99) ~&RAand amino acid (SEQ IMD NO: 100) sequences of 15 W~23/K(l53)E, a KG? analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for lysine at amino acid position 153 of native

KG?.

Figure 48 shows the fucleotide (SEQ 3M No:jo01) and amino acid (SEQ ID NO:102) sequences of AN23/K(153)Q, a KG? analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine for lysine at amino acid position 153 of native

KG?.

Figure 49 shows the nucleotide (SEQ ID NO:103) and amino acid (SEQ ID NO:104) sequences of

&A

23 /Q(1S2)E/Kc153)E, a KG? analog having a deletion of the first 23 amino acids of the N-terminus and a 15 substitution of glutamic acid for glutamine atamn acid position 152 of native KG? and glutamic acid for lysine at amino acid position 153 of native

KG?.

Figure 50 shows the effect of AN23 on streptozotocin-.induced diabetes inSprague-Dawley rats. 20 Dtailed Descri~tp in accordance with the present invention, novel analogs-of KG? are provided. It has now been determined that four of the cysteine residues of native KG? (cysl an c-ysls, and cyslOZ and cyslO 6 are involved in the formation of two disulfide bridges. CYs 4 O is not involved in intramolecular disulfide formation. Hence, KG? contains two small disulfide loops separated by almost 90 amino acids-. Based upon first principals, the determination of which~ cysteine residues are involved in.

the disulfide bridges suggests which cysteines are free to form undesirable intermolecular crosslinkat or intramolec,.lar bonds that cause the protein to adopt an undesirable tertiary structure a conformation that reduces the activity -of the protein).

16 Surprisingly, it has been found that modifying a KGF by deleting or substituting amino acid residues for the cysteine residues corresponding to positions 1 and 15 of KGF (positions 32 and 46 of SEQ ID NO:2) produces a KGF analog having substantially improved stability reduced problems caused by improper refolding, intermolecular disulfide formation and/or protein aggregation). For example, the KGF analogs will generally be purified in a greater yield of soluble, correctly folded protein. Moreover, once the material is purified, it will be more stable to pH, temperature, etc. as compared to the stability of the parent molecule. Although not intended to be bound by theory, it is believed that Cysl and Cys 15 of KGF in addition to 15 forming an intramolecular disulfide bridge and an Nterminal disulfide loop, under certain conditions also exist as free cysteines which are capable of forming intermolecular disulfide bridges, resulting in protein instability and aggregation. Moreover, it has been 20 discovered that deletion of the N-terminal disulfide loop is not important for receptor binding or mitogenic activity.

As used in this invention, a "KGF analog" or a oo* "polypeptide analog of KGF" shall mean any of the described naturally and non-naturally occurring polypeptides differing in structure from a KGF by possessing modifications in peptide sequence corresponding to the 24 amino acid N-terminus of the KGF (amino acids 32 to 55 of SEQ ID NO:2), wherein Cys 1 and CysIs of the KGF (amino acids 32 to 46 of SEQ ID NO:2) are replaced or deleted. The manner by which the cysteines are replaced or deleted is not significant and includes, for example, polypeptide analogs incorporating one or more amino acid deletions and/or substitutions.

Accordingly, the invention provides a family of novel 17 keratinocyte growth factor proteins. This family comprises several groups of proteins.

One group of KGF analogs includes molecules in which the cysteines at positions 1 and 15 of a KGF are replaced with amino acids, including those that do not occur naturally in proteins. Strategies for generating the substitution analogs include using site-directed mutagenesis (Ho et al. (1989), Gene, 27:51-59; Innis et al. "PRC Protocols", Academic Press, Inc., San Diego, CA). [KGF analogs comprising an amino acid substitution are referred to by the residue found at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, followed by that amino acid position in parentheses and the new amino acid. For instance, an 15 analog comprising a cysteine to serine substitution at amino acid position 15 of KGF (position 46 of SEQ ID NO:2) is referred to as Preferably, the cysteine is converted to a neutral amino acid such as glycine, valine, alanine, leucine, isoleucine, tyrosine, 20 phenylalanine, histidine, tryptophan; serine, threonine and methionine, with serine, threonine and alanine being most preferred because of their chemical similarity to cysteine. Example 1 details the generation of C(1,15) using partial gene synthesis (in conjunction with other recombinant techniques) followed by recombinant expression in a stably transformed bacterial host.

Another group of KGF analogs includes molecules that have the cysteines at positions 1 and deleted from KGF. Different strategies may be employed in developing such KGF analogs, such as N-terminal truncations and site-specific deletions, or a combination of both.

An "N-terminal truncation" refers to a modification of a KGF wherein 1 to 24 N-terminal amino acid residues of the KGF (amino acids 32 to 55 of SEQ ID NO:2), including Cysl and Cysl 5 have been deleted.

18 [KGF analogs comprising a truncation of amino acids will be referred to by the residue deleted at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, beginning with the site of the deletion and by the number of residues deleted. For instance, a KGF analog comprising an N-terminal truncation of 24 residues of the KGF (residues 1-55 of SEQ ID NO:2) will be referred to as a "AN24" analog.] Specifically included within this group are AN23 analogs of native KGF wherein one or more of amino acid residues 41-154 (amino acids 72-185 of SEQ ID NO:2), specifically including amino acid residues 123-133 (amino acids 154- 164 of SEQ ID NO:2), are deleted or substituted with a neutral residue or negatively charged residue selected 15 to effect a protein with a reduced positive charge.

Preferred residues for modification are Arg 4 1 Gln 43 Lys 55 Lys 95 Lys 1 28 Asn 137 Gln 1 38 Lys 1 39 Arg 144 *Lys 147 Gln 1 52 Lys 153 or Thr 154 with Gln 138 Lys 1 39 Arg,1 4 4 Lys 14 7 Gln 15 2 or Lys 1 5 3 being more preferred and 20 Arg 144 being most preferred Also included within this group are AN23 analogs of native KGF having loop-forming modifications within a loop-forming region of Asn 1 1 5 Hisl16-Tyr117-Asnl18-Thrl9 (amino acids 146-150 of SEQ ID NO:2), preferably including a charge-change modification of amino acid residue 116, more preferably the substitution of Gly at position 116. Further still, included in this group are AN23 analogs of native KGF having one or more amino acid substitutions, deletions or additions within a region of 123-133 (amino acids of 154-164 SEQ ID NO:2) of native KGF.

Example 1 details the generation of systematic N-terminal truncations accomplished using partial gene synthesis, in conjunction with other recombinant techniques, followed by recombinant expression in a stably transformed bacterial host. Such exemplified Nterminal truncations include AN15 to AN24. Moreover, 19 Example 3 details expression in mammalian cell culture cells of DNA encoding native KGF and heterogeneous

N-

terminal glycosylated isoforms, the purification of preferably a glycosylated isoform having an N-terminal truncation of amino acids 1-23 of the mature form of native KGF.

In contrast, a site-specific deletion refers to a modification of a KGF wherein one or more amino acid residues Cysl or Cys 15 are removed. When a Cysl or Cys 1 s of the KGF is specifically deleted, the analog is one amino acid shorter than the KGF. [KGF analogs comprising an amino acid deletion are referred to by the residue found at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, followed by that amino acid position in parentheses, and a negative sign. For instance, an analog within this group comprising a deletion of cysteine at position 15 of the KGF (position 36 of SEQ ID.NO:2) is referred to as The site-specific 20 deletions may be generated using site directed mutagenesis, as described above.

Also included within this group are analogs in which Cys 1 and Cys 15 of a KGF are removed through truncation and deletion. For example, representative KGF analogs comprise the truncation of the first three amino terminal residues (Cys-Asn-Asp) of the KGF or the truncation of the first eight amino acids (Cys-Asn-Asp- Met-Thr-Pro-Glu-Gln) of the KGF coupled with the deletion of cysteine at amino acid position 15 of KGF (these analogs are referred to as AN3/C(15)- and N8/C(15)-, respectively). As a methionine residue occurs naturally at the fourth and ninth amino acid position in native KGF, no additional Met codon is required to enable proper initiation of translation.

A still further group includes molecules in which the cysteines at positions 1 and 15 of KGF are 20 replaced through truncation and substitution. For example, representative KGF analogs are AN3/C(15)S, and AN8/C(15)S. Such analogs comprise the truncation of the first three amino-terminal residues of a KGF or the deletion of the first eight amino-terminal residues of a KGF coupled with the substitution of cysteine at amino acid position 15 with another amino acid, for instance, serine.

When the KGF analogs are biologically generated, are the products of cellular expression as opposed to the products of solid state synthesis, proteolytic or enzymatic derivatization of naturallyoccurring products, etc., the nucleic acids encoding :o such polypeptides, will differ in one or more 15 nucleotides as compared to the native KGF nucleotide sequence. Such polynucleotides may be expressed and the resultant polypeptide purified by any one of a number of recombinant technology methods known to those skilled in the art.

20 DNA sequences coding for all or part of the KGF analogs may include among other things the incorporation of codons "preferred" for expression in selected host cells coli expression codons"); the provision of sites for cleavage by restrictionenzymes; and the.provision of additional initial, terminal, or intermediate nucleotide sequences an initial methionine amino acid residue for expression in E. coli cells), to facilitate construction of readily expressed vectors.

The present invention also provides recombinant molecules or vectors for use in the method of expression of the polypeptides. Such vectors may be comprised of DNA or RNA and can be circular, linear, single-stranded or double-stranded in nature and can be naturally-occurring or assemblages of a variety of components, be they naturally-occurring or synthetic.

21 Many examples of such expression vectors are known. The components of the vectors, e.g. replicons, selection genes, enhancers, promoters, and the like, may be obtained from natural sources or synthesized by known procedures. In each case, expression vectors useful in this invention will contain at least one expression control element functionally associated with the inserted nucleic acid molecule encoding the KGF polypeptide analog. This control element is responsible for regulating polypeptide expression from the nucleic acid molecules of the invention. Useful control elements include, for example, the lac system, the crp system, the operators and promoters from phage X, a glycolytic yeast promoter, a promoter from the yeast acid phosphatase gene, a yeast alpha-mating factor, and promoters derived from adenovirus, Epstein-Barr virus, polyoma, and simian virus as well as those from various retroviruses. However, numerous other vectors and control elements suitable for procaryotic or eucaryotic expression are known in the art and may be employed in the practice of this invention.

Examples of suitable procaryotic cloning vectors may include plasmids from E. coli pBR322, col El, pUC, and the F-factor), with preferred plasmids being pCFM1156 (ATCC 69702), pCFM1656 (ATCC 69576) and PCFM3102 (described in the Examples section, below).

Other appropriate expression vectors of which numerous types are known in the art for mammalian, insect, yeast, fungal and bacterial expression can also be used for this purpose. The transfection of these vectors into appropriate host cells can result in expression of the KGF analog polypeptides.

Host microorganisms useful in this invention may be either procaryotic or eucaryotic. Suitable procaryotic hosts include various E. coli HB101, DHC5, DH10, and MC1061), Pseudomonas, Bacillus, 22 and Streptomyces strains, with E. coli being preferred.

Suitable eucaryotic host cells include yeast and other fungi, insect cells, plant cells and animal cells, such as COS COS-1 and COS-7) and CV-1 monkey cell lines, 3T3 lines derived from Swiss, Balb-c or NIH cells, HeLa and L-929 mouse cells, and CHO, BHK or HaK hamster cells. Depending upon the host employed, recombinant polypeptides produced in accordance herewith will be glycosylated with mammalian or other eucaryotic carbohydrates or may be non-glycosylated.

The preferred production method will vary depending upon many factors and considerations; the optimum production procedure for a given situation will be apparent to those skilled in the art through minimal 15 experimentation. The resulting expression product may then be purified to near homogeneity using procedures :known in the art. A typical purification procedure for procaryotic cell production involves rupturing the cell walls by high pressure or other means, centrifugation or 20 filtration to remove cellular debris followed by ion exchange chromatography of supernatant or filtrate and, finally, hydrophobic interaction chromatography. If the analog is expressed in insoluble form, another purification technique involves first solublizing the inclusion bodies containing the analogs followed by ion exchange chromatography, then refolding of the protein, and, finally, hydrophobic interaction chromatography.

Exemplary purification techniques are taught in WO 96/ 11952.

Generally, WO 96/11952 teaches a method for purifying a keratinocyte growth factor comprising: (a) obtaining a solution comprising the KGF; binding the KGF from the solution of part to a cation exchange resin; eluting the KGF in an eluate solution from the cation exchange resin; either passing the eluate solution from part through an appropriate molecular 23 weight exclusion matrix or performing hydrophobic interaction chromatography on the eluate Solution of part and recovering the KGF from the molecular weight exclusion matrix or hydrophobic interaction chromatography.

of course, the analogs may be rapidly screened to assess their physical properties. The Examples section set forth various well-known stability assays, although the specific assay-used to test the analog is not critical.. Moreover, the level of biological activity receptor binding and/or affinity, mitogenic, cell proliferative and/or in vivo activity) may also be tested using a variety of assays, some of .which are set forth in the Examples section. Numerous assays are well-known and can be used to quickly screen the KGF analogs to determine whether or not they possess acceptable biological activity. one such assay specifically tests the KGF analogs for the ability to bind to the KGF receptor (KGFR) by competing with 20 1 2 5 1-KGF binding (Bottaro et al. (1990), J. Biol. Chem., 2,U:12767-12770; Ron et al. (1993), Eiol. Chem., 2.:2984-2988). An alternative method for assaying KGFR/KGF analog interactions involves the use of techniques such as real time biospecific interaction analysis (EtA) (Felder et al. (1993), Molecular& Cellular Biology, 11:1449-1455). Additionally a mitogenic assay can be utilized to test the ability of the KGF analogs to stimulate DNA synthesis (Rubin et: al.

(1989) supra). Finally, cell proliferative assays can be utilized to test the ability of the KGF analogs to stimulate cell proliferation (Falco, ec al. (1988), Oncogene, 2,:573-578). Using any of the aforementioned assay systm, KGF analogs can be rapidly screened for their biological activity.

in a preferred embodiment, the present invention is directed to KGF analogs which retain the 24 full at least substantially similar) in vitro or in vivo biological activity to that of native

KGF.

Exemplary KGF analogs with these properties, as determined by one or more of the above assays, are C(1,15)S, AN3/C(15)S, AN3/C(15)-, AN8/C(15)S, AN8/C(15)-, AN15, AN16, AN17, AN18, AN19, AN20, AN21, AN22, AN23, AN24 or AN23/R(144)Q.

The KGF analogs may be further modified to contain additional chemical moieties not normally a part of the peptide. Such derivatized moieties may improve the solubility, absorption, biological half life, and the like of the KGF analog. The moieties may alternatively eliminate or attenuate any undesirable side effects of the protein and the like. Moieties capable of mediating such effects are disclosed, for example, in REMINGT'N'S PHARMACEUTICAL SCIENCES, 18th ed., Mack Publishing Co., Easton, PA (1990). Covalent modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide 20 with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues Creighton (1983), PROTEINS: STRUCTURE AND MOLECULE o' *PROPERTIES, W.H. Freeman Co., San Francisco, pp. 79-86). Polyethylene glycol is one such chemical moiety which has been used in the preparation of therapeutic protein products. For some proteins, the attachment of polyethylene glycol has been shown to protect against proteolysis, Sada, et al.(1991), J.

Fermentation Bioengineering, 21:137-139 and methods for attachment of certain polyethylene glycol moieties are available. Se U.S. Patent No. 4,179,337, Davis et al., "Non-Immunogenic Polypeptides," issued December 18, 1979; and U.S. Patent No. 4,002,531, Royer, "Modifying enzymes with Polyethylene Glycol and Product Produced Thereby, issued January 11, 1977. For a. review, see Abuchowski et al., in Enzymes as Drugs. (Holcerberg and Roberts, (eds.) pp. 367-383 (1981)). For polyethylene glycol, a variety of means have been used to attach the polyethylene glycol molecules to the protein.

Generally, polyethylene glycol molecules are connected to the protein via a reactive group found on the protein. Amino groups, such as those on lysine residues or at the N-terminus, are convenient for such attachment. For example, Royer Pat.

No. 4,002,531, above) states that reductive alkylation was used for attachment of polyethylene glycol molecules to an enzyme. EP 0 539 167. published April 28, 1993, Wright, "Peg Imidates and Protein Derivates Thereof* states that peptides and organic compounds with free amino group(s) are modified with an imidate derivative 15 of PEG or related water-soluble organic polymers.

U.S.

Patent No. 4,904,584, Shaw, -issued February 27, 1990, relates to the modification of the number of lysine *residues in proteins for the attachment of polyethylene glycol molecules via reactive amine groups.

20 in yet another embodiment, the present invention is directed to a single-dose administration unit of a medicinal formulation, which can be safely administered parenterally or orally to treat a disease in a warm-blooded animal (such as a human). Such medicinal formulation may be in the form of a lyophilized or otherwise dehydrated therapeutic or diagnostic which can be reconstituted by the addition of a physiologically acceptable solvent. The solvent may be any media such as sterile-water, physiological saline solution, glucose solution or other aqueous carbohydrates polyols such as mannitol, xylitol or glycerol) which is capable of dissolving the dried composition, which is compatible with the selected administration route and which does not negatively interfere with the active principle and the reconstitution stabilizers employed. In a specific 26 embodiment, the present invention is directed to a kit for producing the single-dose administration unit. The kit contains both a first container having a dried protein and a second container having an aqueous formulation comprising a reconstitution stabilizer. As for the concentration of the protein in the solution, the solution volume which is charged into each container, and the capacity of the containers (interrelated parameters which can be suitably modified, depending upon the desired concentration of active principle in the end-dosage unit), these may vary within wide ranges well-known to skilled artisans.

KGF analogs according to the invention may be useful. as therapeutic and diagnostic agents and as 15 research reagents. Thus the KGF analogs may be used in in vitro and/or in vivo diagnostic assays to quantify the amount of KGF in a tissue or organ sample or to determine and/or isolate cells which express KGFR (Bbttaro-et al. (1990), J. Biol. Chem., 265:12767-12770; 20 Ron et al. (1993), J. Biol. Chem., 268:2984-2988). In assays of tissues or.organs there will be less radioactivity from 12 5I-KGF analog binding to KGFR, as compared to a standardized binding curve of 12

SI-KGF

*i analog, due to unlabeled native KGF binding to KGFR.

Similarly, the use of 125 I-KGF analog may be used to detect the presence of KGFR in various cell types.

This invention also contemplates the use of a KGF analog in the generation of antibodies made against the peptide, which antibodies also bind to native KGF.

In this embodiment, the antibodies are monoclonal or polyclonal in origin and are generated using a KGF analog. The resulting antibodies bind preferentially to native KGF, preferably when that protein is in its native (biologically active) conformation. These antibodies can be used for detection or purification of the native KGF.

27 Moreover, the invention contemplates the use of the KGF analogs in the discovery of high affinity or low affinity KGF binding molecules having therapeutical applications, for example, as a way for efficient KGF delivery or as an inhibitor for KGF activity. The thermal stability of the KGF analogs is important to identify such binding molecules in physiological conditions at 37'C) since their affinity for KGF could be strongly temperature-dependent and may be 10 unpredictable from the affinity observed at 4'C.

For in vivo uses, the KGF analogs may be formulated with additives. Such additives include .buffers, carriers, stabilizers, excipients, preservatives, tonicity adjusting agents, anti-oxidants and the like viscosity adjusting agents or extenders). The selection of specific additives will depend upon the storage form liquid or lyophilized) and the modes of administering the KGF analog. Suitable formulations, known in the art, can be found in REDMNGTON'S PHARMACEUTICAL SCIENCES (latest edition), Mack Publishing Company, Easton, PA.

The KGF analogs may be applied in therapeutically effective amounts to tissues specifically characterized by having damage to or clinically insufficient numbers of non-fibroblast epithelium cells. Areas in which KGF analogs may be successfully administered include, but are not limited to: the stimulation, proliferation and differentiation of adnexal structures such as hair follicles, sweat glands, and sebaceous glands in patients with burns and other partial and full-thickness injuries; accelerated reepithelialization of lesions caused by epidermolysis bullosa, which is a defect in adherence of the epidermis to the underlying dermis, resulting in frequent open, painful blisters which can cause severe morbidity; preventing chemotherapy-induced alopecia and treating 28 male-pattern baldness, or the progressive loss of hair in men and women; treating gastric and duodenal ulcers; treating inflammatory bowel diseases, such a Crohn's disease (affecting primarily the small intestine) and ulcerative colitis (affecting primarily the large bowel); preventing or reducing gut toxicity in radiation and chemotherapy treatment regimes through treatment pretreatment and/or postreatment) to induce a cytoprotective effect or regeneration or both; stimulating the production of mucus throughout the gastrointestinal tract; inducing the proliferation and differentiation of type II pneumocytes, which may help treat or prevent diseases such as hyaline membrane Sdisease infant respiratory distress syndrome and bronchopulmonary dysplasia) in premature infants; stimulating the proliferation and differentiation of the bronchiolar and/or alveolar epithelium with acute or chronic lung damage or insufficiency due to inhalation injuries (including high oxygen levels), emphysema, use of lung damaging chemotherapeutics, ventilator trauma or other lung damaging circumstances; increasing liver function to treat or prevent hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and/or toxic insults to the liver; inducing corneal cell regeneration, for example in the treatment of corneal abrasion; inducing epithelial cell regeneration to treat progressive gum disease; inducing regeneration of tympanic epithelial cells to treat ear drum damage and treating or preventing the onset of diabetes mellitus or as an adjunct in the setting of islet cell transplantation.

A patient in need of proliferation of nonfibroblast epithelial cells will be administered an effective amount of a KGF analog. An "effective amount" is that amount of the KGF analog required to elicit the desired response in the patient being treated and will, 29 thus, generally be determined by the attending physician. Factors influencing the amount of KGF analog administered will include the age and general condition of the patient, the disease being treated, etc. Typical dosages will range from 0.001 mg/kg body weight to 500 mg/kg body weight.

The KGF analog may be safely administered parenterally via IV, IT, IM, SC, or IP routes), orally or topically to warm-blooded animals (such as humans). The KGF analog may be used once or administered repeatedly, depending on the disease and the condition of the patient. In some cases, the KGF analog may be administered as an adjunct to other therapy and also with other pharmaceutical preparations.

The following examples are included to more fully illustrate the present invention. It is understood that modifications can be made in the procedures set forth, without departing from the spirit of the invention.

EXAMPLES

Standard methods for many of the procedures described in the following examples, or suitable alternative procedures, are provided in widely recognized manuals of molecular biology such as, for example, Molecular Cloning, Second Edition, Sambrook et al., Cold Spring Harbor Laboratory Press (1987) and Current Protocols in Molecular Biology, Ausabel et al., Greene Publishing Associates/Wiley Interscience, New York (1990).

EXAMPLE 1: Preparation of DNA Coding for KGF and KGF Analogs The cloning of the full-length human KGF gene (encoding a polypeptide with the sequence of native KGF) 30 was carried out both by polymerase chain reaction

(PCR)

of RNA from an animal cell and by PCR of chemically synthesized coli optimized codon) oligonucleotides ("OLIGOs) Both procedures are described below: PCR amplification using RNA isolated from cells known to produce the polypeptide was performed.

Initially, cells from a human fibroblast cell line AG1523A (obtained from Human Genetic Mutant Cell Culture Repository Institute For Medical Research, 10 Camden, New Jersey) were disrupted with guanidium thiocyanate, followed by extraction (according to the method of Chomyzinski et al. (1987), Anal. Biochem., 122:156). Using a standard reverse transcriptase protocol for total RNA, the KGF cDNA was generated.

PCR (PCR#1) amplification of the KGF gene was carried out using the KGF cDNA as template and primers OLIGO#1 and OLIGO#2 that encode DNA sequences immediately and 3 1 of the KGF gene [Model 9600 thermocycler (Perkin-Elmer Cetus, Norwalk, CT); 28 cycles; each cycle consisting of one minute at 94°C for denaturation, two minutes at 60°C for annealing, and three minutes at 72°C for elongation]. A small aliquot ooo *of the PCR#1 product was then used as template for a second KGF PCR (PCR#2) amplification identical to the cycle conditions described above except for a annealing temperature. For expression cloning of the KGF gene, nested PCR primers were used to create convenient restriction sites at both ends of the KGF gene. OLIGO#3 and OLIGO#4 were used to modify the KGF DNA product from PCR#2 to include Mlul and BamffI restriction sites at the 5' and 3' ends of the gene, respectively (PCR#3; 30 cycles; each cycle consisting of one minute at 94°C for denaturation, two minutes at for annealing, and three minutes at 72*C for elongation]. This DNA was subsequently cut with Mlul and BamHI, phenol extracted, and ethanol precipitated.

31 It was then resuspended and ligated (using T4 ligase) into a pCFM1l56 plasmid (Figure 2A) that contained a "RSH" signal sequence to make construct RSH-KGF (Figure 3).

The ligation products were transformed (according to the method of Hanahan (1983), J. Mol.

Biol., 1j6:557) into E. coli strain FM5 (ATCC: 53911) and plated onto LB+kanamycin at 28C. Several transformants were selected and grown in small liquid cultures containing 20 g/mL kanamycin. The RSH-KGF plasmid was isolated from the cells of each culture and DNA sequenced. Because of an internal NdeI site in the KGF gene, it was not possible to directly clone the native gene sequence into the desired expression vector 15 with the bracketed restriction sites of Ndel and BamHI.

This was accomplished as a three-way ligation. Plasmid RSH-KGF was cut with the unique restriction sites of BsmI and SstI, and a -3 kbp DNA fragment (containing the 3' end of the KGF gene) was isolated following electrophoresis through a 1% agarose gel. A PCR (PCR#4) was carried out as described for PCR#3 except for the substitution of OLIGO#5 for OLIGO#3. The PCR DNA product was then cut with NdeI and BsmI and a 311 bp DNA fragment was isolated following electrophoresis through a 4% agarose gel. The third piece of the ligation is a 1.8 kbp DNA fragment of pCFM1156 cut with Ndel and SstI isolated following electrophoresis through a 1% agarose gel. Following ligation (T4* ligase), transformation, kanamycin selection and DNA sequencing as described above, a clone was picked containing the construct in Figure 4 and the plasmid designated KGF. Because of an internal ribosomal binding site that produced truncated products, the KGF DNA sequence between the unique KpnI and EcoRI sites was replaced with chemically synthesized OLIGOs 32 (OLIGO#6 through OLIGO#l1) to minimize the use of the internal start site (Figure 5) OLIG0#1 (SEQ ID NO:7): 5S-CAATGACCTAGGAGTAACAATCAAC.

3 OLIGO*2 (SEQ ID NO: 5 -AAAACAAACATAAMTGCACAAGTCC-A- 3 OLIGO* 3 (SEQ ID NO: 5 -ACAACGCGGCATGCATACTA- 3 OLIGO*4 (SEQ ID NO:1O): -ACAGGATCCTATAGTATTGCCATAGGA 3' (SEQ ID NO:11): 10 5 '-ACACATATGTGCAATr.ACATGAcTCCA...3 OLIGO*6 (SEQ ID NO:12): 5-CTGCGTATCGACAAACGCGGCAAGTCAGGCACC.3' OLIGO@7 (SEQ ID NO:13): 5*AGGTAAAACAATATTGATCTCGT3 OLIGO#8 (SEQ ID NO:14): TGATAAGTTMcG OLIGO*9 (SEQ ID 5'TTGGGCTATTCCCTTTGTCCGTC3' OLIGOtlO (SEQ ID NO:16): 5' -ACAGCAACAGTACGGATTTCCATAATATrGTAGTTGTTTTCATC-3' OLIGO#11 (SEQ ID NO:17): 5'-AATCAGAT'cAACACTTTGAGCAACGATACCA-.3' The OLIGOs were phosphorylated with T4 polynucleotide kinase and then heat denatured. The single-stranded OLIG0s were then allowed to form a d~s MIA fragment by allowing the temperature to slowly decrease to room temperature. T4 ligase was then used to covalently link both the internal OLIGO sticky-ends and the whole ds OLIGO f ragment to the KGF plasmid cut with KpnI and EcoRI. The new plasmid was designated KGF(dsd).

A completely E. coli codon-optimized KGF gene was constructed by PCR amplification of chemically synthesized OLIGOS #12 through 24d.

-33 0LIGO*12 (SEQ ID NO:18): 5'-AGTTTGATCTAGAGAG-3' OLIGO#13 (SEQ ID NO:19): S'-TCAAAACTGGATCCTATTAA-3' 0LI00#14 (SEQ ID

-GTTACAAGAGATAAAGGACAAG

ACCGAAAAGCACAGTATCCACCG6CT3 OLIGO#1S (SEQ IV NO:21):

-CACACCCGTAGCTACGACTACATGGGGTGGCATCGT.

GTTCGTCGTCTTCTGCCGTACCCAGGGTATCGTACGAAA-

3 OLIGO*16 (SEQ IV N0:22): 5'-CGTGGTA AAGT AAAGGTACCCAGGAAACAA~CATAACTC ATGGAAATCCGTAC=TGTTGTGTA=MTC...3' OLIGO#.7 (SEQ ID N0:23): ~3 0LI00018 (SEQ ID NO:24): CCACAACGGTGGTGAATGTrCGGcTCTAcCAGAGGr.3' OLIGO#19 (SEQ ID -ATCCCGGI'rCGTGGTAAAAACCAA AAGAACAAACCCTC AC? CCTGCCGATGGCAATCACTTAATAGGATCCAGTI'TTGA- 3 OLIGO#2O (SEQ ID NO:26):5'-TACGTACrGCGGG3' OLIGO#21. (SEQ ID NO:27) :5'-CTTACCACGTTITGTCGATA-3' OLIGO#22 (SEQ ID NO2)5-TCACC7 TGA3 OLIGO#23 (SEQ ID NO:29):5'-CCAGrGA,%IL-li~rG.3' OLIGO#24 (SEQ ID NO:30) :5'-GAACCGGGATACCTTTCTG-3' OLIGOs #12 Ehrough 24 were designed so that the entire DNA sequence encoding native KGF was represented by OLIGOs from either. the OWatsono or the "Crick" strand and upon PCR amplification would produce the desired double-stranded DNA sequence (Figure 6) Model 9600 thermocycler, Perkin-Elmer Cetus]; 21 cycles, each cycle consisting of 31 seconds-at 94*C for denaturation, 31. seconds at 50 0 C for annealing, and 31 seconds at 73*C for elongation; following-the 21 cycles the PCR was finished wit~h a final elongation step of 7 34 minutes]. After PCR amplification, the DNA fragment was cut with Xbal and BamHI and the 521 bp fragment ligated into the expression plasmid pCFM1156 cut with the same enzymes. PCR#5 utilized the outside primers (100 pmoles/100 4l rxn) OLIGO#12 and OLIGO#13 and 1 4l/100 il rxn of a KGF template derived by ligation (by T4 ligase) of OLIGO#14 through OLIGO#19 (OLIGO#15 through OLIGO#18 were phosphorylated with T4 polynucleotide kinase) using OLIGO#20 through OLIGO#24 as band-aid oligos (Jayaraman •p 10 et al. (1992), Biotechniques, 12:392) for the ligation.

The final construct was designated KGF (codon optimized).

All of the KGF analogs described herein are composed in part from DNA sequences found in KGF(dsd) or KGF(codon optimized), or a combination of the two. The :sequences are further modified by the insertion into convenient restriction sites of DNA sequences that encode the particular KGF analog amino acids made utilizing -one or more of the above-described techniques for DNA fragment synthesis. Any of the analogs can be generated in their entirety by the above described techniques. However, as a part of the general OLIGO design optimized E. coli codons were used where appropriate, although the presence of E. coli optimized codons in part or in toto of any of the genes where examined did not significantly increase the yield of protein that could be obtained from cultured bacterial cells. Figures 7 to 24 and 37 to 50 set forth by convenient example particular KGF analog nucleotide and amino acid sequence constructions: C(1,15)S (Figure 7); AN3/C(15)S (Figure AN3/C(15)- (Figure AN8/C(15)S (Figure 10); AN8/C(15)- (Figure 11); AN15 (Figure 12); AN16 (Figure 13); AN17 (Figure 14); AN18 (Figure AN19 (Figure 16); AN20 (Figure 17); AN21 (Figure 18); AN22 (Figure 19); AN23 (Figure 20); AN24 (Figure 21); C(1,15)S/R(144)E (Figure 22); C(1,15)S/R(144)Q 35 (Figure 23); N23/R(144)Q (Figure 24); C(1,15,40)S (Figure 36) C(1,15,102)S (Figure 37); C(1,15,102,106)s (Figure 38) N23/N(137)E (Figure 39) N23/K(139)E (Figure 40) N23/K(139)Q (Figure 41) AN23/R(144)A (Figure 42) N23/R(144)E (Figure 43) AN23/R(144)L (Figure 44) AN23/K(147)E (Figure45) N23/K(147)Q (Figure 46) N23/K(153)E (Figure 4 7 N23/K(153)Q (Figure 48). and AN23/Q(152)E/K(153)E (Figure4 9 All the KGF analog constructions described herein were DNA sequence confirmed.

%EXAMPLE2: Production in E. col A. Expression of KGF Analogs Three different expression plasmids were utilized in the cloning of the KGF analog genes. They were pCF1156 (ATCC# 69702), pCFM1656 (ATCC# 69576), and pCFM3102 (Figures 2A, 2B and 2C, respectively). The plasmid p3102 can be derived from the plasmid pCFM1656 by making a series of site-directed base changes with PCR overlapping oligo mutagenesis. Starting with the BglrZ site (pCFM1656 plasmid bp 180) immediately 5' to the plasmid replication promoter, PcopB, and proceeding toward the plasmid replication genes, the base pair changes are as follows: 36 DCFM1656 bn 204 428 509 617 677 978 992 1002 1005 1026 1045 1176 1464 15 2026 2186 2479 .1% t bD in nCFM1656

T/A

A/T

G/C

G/C

T/A

G/C

A/T

C/G

A/T

C/G

G/C

G/C

G/C

C/G

A/T

AMT

TCAC

TCCGAGC

AGGCTCG

G/C

G/C

A/T

b, chanced to in nCFM312

C/G

G/C

A/T

insert two G/C bp

T/A

C/G

A/T

C/G

T/A

T/A

T/A

T/A

T/A

bp deletion

T/A

T/A

QiA

CAGT

bp deletion

A/T

A/T

T/A

2498-2501 2641-2647 3441 3452 3649 4556 (SEQ ID (SEQ ID insert bps NO:67) 5'-GAGCCACTAGTGTCGACCTGCAG-3' NO:68) S S As seen above, pCFM1156, pCFM1656 and pCFM3102 are very similar to each other and contain many of the same restriction sites. The plasmids were chosen by convenience, and the vector DNA components can be easily exchanged for purposes of new constructs. The host used for all cloning was E. coli strain FM5 (ATCC: 53911) and the transformations were carried out (according to the method of Hanahan (1983), supra) or by electroelution with a Gene Pulserm transfection apparatus (BioRad Laboratories, Inc., Hercules, CA) according to the manufacturer's instructions.

Initially, a small, freshly cultured inoculum of the desired recombinant E. coil clone harboring the 37 desired construct on one of the three pCFM vectors was started by transferring 0.1 mL of a frozen glycerol stock of the appropriate strain into a 2 L flask containing 500 mL of Luria broth. The culture was shaken at 30*C for 16 hours, after which the culture was transferred to a 15 L fermentor containing 8 L of sterile batch medium (Tsai, et al. (1987), J. Industrial Microbiol., 2:181-187).

Feed batch fermentation starts with the 10 feeding of Feed 1 medium (Tsai, et al. (1987), supra). When the OD600 reached 35, expression of the desired KGF analog was induced by rapidly raising the 0 culture temperature to 37"C for two hours then up to o°°O 42"C to denature the CI repressor. The addition of Feed 1 was discontinued in favor of Feed 2, the addition rate of which was initiated at 300 mL/hr. Feed 2 comprised 175 g/L trypticase-peptone, 87.5 g/L yeast extract, and 260 g/L glucose. After one hour at 42*C, the culture temperature was decreased to 36"C, where this temperature was then maintained for another 6 hours.

The fermentation was then halted and the cells 0were harvested by centrifugation into plastic bags 'oo placed within 1 L centrifuge bottles. The cells were pelleted by centrifugation at 400 rpm for 60 minutes, after which the supernatants were removed and the cell paste frozen at Following expression of the various

KGF

analogs in E. coli, native KGF, C(1,15)S, C(1,15)S/R(144)E, C(1,15)S/R(144)Q, AN15, AN23, and AN23/R(144)Q proteins were purified using the following procedure. Cell paste from a high cell density fermentation was suspended at .4'C in 0.2 M NaCI, 20 mM NaP0 4 pH 7.5 as a 10-20% solution (weight per volume) using a suitable high shear mixer. The suspended cells were then lysed by passing the solution through a homogenizer (APV Gaulin, Inc., Everett, MA) three times.

38 The outflowing homogenate was cooled to 4-8"c by using a suitable heat exchanger. Debris was then removed by centrifuging the lysate in a J-6BT centrifuge (Beckman Instruments, Inc., Brea, CA) equipped with a JS 4.2 rotor at 4,200 rpm for 30-60 min. at 4C. Supernatants were then carefully decanted and loaded onto a previously prepared 450 mL (5 cm x 23 cm) column of S- Sepharose Fast Flow?" resin (Pharmacia, Piscataway,

NJ)

equilibrated with 0.2 M NaCI, 20 mM NaP0 4 pH 7.5 at 4C. Next, the column was washed with five column volumes (2250 mL) of 0.4 M NaCI, 20 mM NaPO 4 pH 7.5 at 4"C. The desired protein was eluted by washing the column with 5 L of 0.5 M NaCI, 20 mM NaP0 4 pH 50 mL fractions were collected and the A 2 8 0 of the 15 effluent was continuously monitored. Fractions identified by A 280 as containing eluted material were then analyzed by SDS-PAGE through 14% gels to confirm o°othe presence of the desired polypeptide.

Those fractions containing proteins of 20 interest were then pooled, followed by the addition of an equal volume of distilled water. The diluted sample was then loaded onto a previously prepared a 450 mL (5 cm x 23 cm) column of S-Sepharose Fast Flow equilibrated with 0.4 M NaCI, 20 mM NaiO 4 pH 6.8 at- 4C. The column was washed with 2250 mL of 0.4 M NaCI, mM NaP0 4 pH 6.8 and the protein eluted using a column volume linear gradient ranging from 0.4 M NaCl, mM NaPO 4 pH 6.8 to 0.6 M NaCI, 20 mM NaPO 4 pH 6.8.

Again, 50 mL fractions were collected undeF constant A280o monitoring of the effluent. Those fractions containing the protein (determined by 14% SDS-PAGE) were then pooled, followed by concentration through a membrane (10,000 molecular weight cutoff) in a 350cc stirring cell (Amicon, Inc. Mayberry, MA) to a volume of 30-40 mL.

39 The concentrate was then loaded onto a previously generated 1,300 znL (4.4 cm x 85 cm) colun of resin (Pharmacia) equilibrated in column buffer comprising 1X PBS (Dulbecco's Phosphate Buffered Saline, "D-PBS", calcium and magnesium-free) or 0.15 m NaCi, 20 mM NaPO 4 pH 7.0. After allowing the sample to run into the column, the protein was eluted from the gel filtration matrix using column buffer. Thereafter, mL fractions were recovered and those containing the analog (determined by 14% SDS-PAGE) were pooled.

Typically, the protein concentration was about 5-10 mg/mL in the resultant pool. All of the above procedures were performed at 4-8'C, unless otherwise specified.

is1 An alternative purification procedure was used to purify native KGF, C (1,15) S and AN23. .The procedure involves the following steps, and unless otherwise specified, all procedures, solutions and materials were conducted.at 23 S.C.

Upon completion of the production phase of a bacterial fermentation, the cell culture was cooled to 4-8*C and the cells harvested by centrifugation or a similar process. on the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, was suspended in a mild buffer solution of 20 mM NaPO0 4 0.2 X NaCl, pH 7.5, weighing about five times that of the cell paste to be suspended.

The cells were dispersed to a homogeneous solution using a high shear mixer. The temperature of the cell paste dispersion was maintained at 4-8'C during homogenization.

The cells were then lysed by pressure, for example by passing the cell paste dispersion twice through an appropriately-sized cell homogenizer. The homogenate was kept chilled at 5 3 0 C. To clarify the 40 cell lysate, a previously prepared depth filter housing (Cuno, Inc., Meriden, CT) equipped with a filter having an appropriate amount of filter surface area, equilibrated with a suitable volume of 0.2 M NaC1, 20 mM NaPO 4 pH 7.5, was employed. The equilibration and clarification were performed at 5 3'C. Prior to clarification, an appropriate amount of a suitable filter aid was used to pre-coat the filter and be thoroughly mixed with the cell lysate, after which the 10 lysate was clarified by passing the solution through the filter apparatus. The filter was washed with 0.2 M NaC1, 20 mM NaPO 4 pH 7.5. The filtrate and any subsequent wash were collected in a chilled container of suitable capacity, all the while being maintained at less than Following clarification, the lysate was then passed through a previously prepared a column of SP-Sepharose Fast Flow containing at least 1 mL of resin per 2 g of cell paste. The column of SP-Sepharose Fast Flow was equilibrated with cold (5 0.2 M NaC1, mM NaP0 4 pH 7.5. The temperature of the column was maintained at less than 10'C. The clarified lysate "i (5 t 3"C) was then loaded onto the ion exchange column, with the absorbance at 280 nm (A 2 8 0 of eluate being continuously monitored. After sample loading, the column was washed with cold 0.2 M NaCl, 20 mM NaPO4, pH followed by washing with 0.3 M NaCl, 20 mM NaPO 4 pH 7.5 at 23 To elute the desired protein, a linear gradient ranging from 0.2-1 M NaCl, 20 mM NaPO 4 pH was used. Bulk product was collected in several fractions on the basis of the A 280 of the eluate.

Following elution, these fractions were pooled and the volume noted.

To oxidize free sulfhydryl groups, an oxidation step was performed. For proteins with altered 41 cysteine patterns, as compared to native KGF, an oxidizing agent cystamine dihydrochloride or another appropriate oxidizing agent, for instance, cystine, oxidized glutathione or divalent copper) was added to a final concentration of 1-20 mM and the pH was adjusted to 7-9.5, with a pH of 9.0 0.3 being preferred when cystamine dihydrochloride was used. The oxidation was conducted at 10-30 C for an appropriate period. For the native KGF protein, oxidation was accomplished by adding an appropriate amount of (NH 4 2 SO4 such as 1-2 M (NH 4 2 S0 4 adjusting the pH to 7.5 and holding the temperature at 23 5'C for an appropriate period.

After oxidation, the pH of the solution was 15 adjusted to between 6.5 and 9.5. If necessary, solid

(NH

4 2 S0 4 was added to the solution to a final concentration of 2 M. To remove particulates, the solution was passed through appropriate clarification 2 filters.

The filtered, oxidized product was then subjected to hydrophobic interaction chromatography (HIC). The HIC matrice was Butyl-650M Toyopearl' m resin (Tosohaas, Inc., Montgomeryville, PA). The proteincontaining solution was loaded onto the column, which had been previously equilibrated with 2 M (NH 4 2 S0 4 0.15 M NaCl, 20 mM NaP0 4 pH 7.0. After sample loading, the column was washed with 2 M (NH 4 2

SO

4 0.15 M NaCI, 20 mM NaP0 4 pH 7.0. The desired protein was then eluted using a decreasing linear (N1 4 )2S0 4 gradient ranging from 2-0 M developed in 0.15 M NaCI, 20 mM NaP04, pH When the desired protein began to elute, as indicated by an increase in the A 2 8 0 of the eluate, fractions were collected. Aliquots of each fraction were then analyzed by SDS-PAGE. Those fractions containing the desired protein were then pooled, thoroughly mixed, and the 42 volume of the pool determined, as was the concentration of the protein therein.

The pooled HIC protein-containing eluate was then concentrated and the elution buffer exchanged.

Typically, proteins were concentrated to 5.0-10,0 mg/mL. Ultrafiltration was conducted using an ultrafiltration system equipped with a PTGC Pellicone

M

cassette system (Millipore, Inc., Bedford, MA) with an appropriately sized cut-off membrane After concentration, the sample was diafiltered against an appropriate buffer. The retentate from the concentration step was diafiltered e eagainst 0.15 M NaCI, 20 mM NaPO 4 pH 7.0 until the -conductivity of the retentate was within 5% of the 15 conductivity of the 0.15 M NaCI, 20 mM NaPO 4 pH solution.

In addition, to remove precipitates and bacterial endotoxin that might be present, the concentrated diafiltered protein-containing sample was S 20 passed through a 0.1 pm Posidyne* filter (Pall, Inc., Cortland, NY). After determining the protein concentration of the solution and on the basis of the desired concentration of the final bulk product, the solution was diluted with 0.15 M NaCl, 20 mM sodium phosphate, pH 7.0, to the desired final concentration.

A final aseptic filtration through a 0.22 pm filter was then performed as the final bulk product was transferred to a pyrogen-free container for storage (at about for further formulation.

B. Analysis Analysis was conducted using E. coli-derived, native KGF; C(1,15)S; C(1,15)S/R(144)Q; AN15; AN23 and AN23/R(144)Q.

-43- Conformational Stability The polypeptides were compared by their storage stability, thermal unfolding transition temperatures (Tj, and stability in a broad range of pH conditions.

Storage Stability Figure 25 compares native KGF and C(1,15)S when stored in 20 mM NaPO 4 0.15 M NaC1, pH 7.0 at 37 0 C for 27 hrs. C(1,15)S showed a significantly increased amount of soluble protein relative to native KGF.

Figure 26 compares the ability of native KGF, AN15 (data not shown) and C(1,15)S in PBS and in 50 mM NaPO 4 0.15 M NaCl, pH 7.0, when stored at 37°C for 18 hrs. The recovery of soluble protein is much higher in high phosphate than in PBS.

as well as C(1,15)S showed significantly enhanced stability, as compared with native KGF. AN15 and C(1,15) S also gave -100% recovery in high phosphate, as expected from the result of native KGF.

However, a single preliminary comparative example of storage stability was conducted between C(1,15,40)S, and C(40)S (which is encoded by bases 201 to 684 of SEQ ID NO:1, except that Ser 4 0 is encoded by AGA); and between C(1,15,102), and C(102)S (which is encoded by bases 201 to 684 of SEQ ID NO:1, except that Ser 02 is encoded by AGG). The results (not shown) indicated a decreased stability less soluble protein after being stored at 37 0 However, the amount of soluble, correctly folded C(1,15,40)S protein which was purified from the culture medium was greater than that of C(40)S, suggesting that C(1,15,40)S may in fact be more stable and that the r results from the comparative example are inconclusive. The present invention preferably 22135-00DOC -44includes a KGF analog having other than substitutions at Cys 40 Cys 1 0 2 Cys' 0 6 and more preferably excludes C(1,15,40)S, C(1,15,102)S and C(1,15,40,102,106).

The ability of native KGF, C(1,15)S, AN23, C(1,15)S/R(144)E, C(1,15)S/R(144)Q and AN23/R(144)Q to prevent aggregation at elevated temperatures was also examined.

Samples containing 0.5 mg/mL of protein were prepared in D-PBS. 0.5 mL of each sample was aliquoted into 3 cc type-1 glass vials. The vials were sealed with rubber stoppers and 13 mm flip-off aluminium seals were crimped on. These vials were then placed in a 37°C incubator. At predetermined time intervals, vials were withdrawn and o analyzed for the loss of soluble protein. Visible precipitates were removed by

S

10 centrifuging 250 pL of each sample through a 0.22 pm Spin-X TM filter unit (Costar, Cambridge, MA). Soluble protein in the filtered solutions was subsequently analyzed by

S

size exclusion HPLC. The amount of soluble protein was determined by integrating the S HPLC peak area and plotting the result as a function of incubation time at 37°. The

S

results for native KGF, C(1,15)S, C(1,15)S/R(144)E and C(1,15)S/R(144)Q (the data for *i 15 AN23 and AN23/R (144)Q are not shown) are shown in Figure 27.

The half-lives for the loss of soluble, monomeric protein were then estimated from these kinetic curves. Table 1 show the half-life for remaining soluble KGF upon storage at 37°C for these proteins.

45 Table 1 Half-life for the Loss of Rnoluble. Moomeri c Proteins Protein -t1/2 (dayo) native KGF 0.6 AN23 1.1- C 15) s 1.2 C 15) S/R (144) Q 13.3 AN23 /R144Q .22.3 C (1,1)SIS/R(3.44) E t 38.0 5 5As seen in Table 1, above, and Figure 2 7 the native KGF aggregated the most rapidly, with a solubility half-life of 0.6 days. C(1,15)S/R(2.44)Q, AN23IR(144)Q -and C(1,15)S/R(144.)E showied substantial .increases in the solubilityhalf -life to 13.3, 22.3 and 38 days, respectively.

Themal.n ohnlwa mnondioe b irua dichroism, (CD) at 230 nm using a J-72020 *spectropolarimter (Jasco, Inc., Easton, MD) equipped with a PTC-343 Peltier-type temperature control system.

For CD analysis, separate samples containing 0.1 mg/mL of the polypeptide to be analyzed were prepared in D-PBS (Life Technologies, Inc., Grand Island, For each sample, about 2. 5 mL was loaded into a 10 mm path length rectangular Supras il7 quartz (Heraeus Quarzschmelze, GmbH, Hanau, Germany) fluorescent -cell. (Helima Cells, Inc, -Jamaica, NY). The cell was then placed into the Peltier-type temperature control system inthe spectropolarimeter. Thermal unfolding. was carried- out at a rate of 50*C/hr. Changes in ellipticity were monitored at 230 nm to indicate U~nfolding. The Tm Of each sample was estimated by identifying a temperature 46 at which 50% of protein molecules in the solution were unfolded (Biophysical Chemistzy, Cantor and Schimmnel (eds), W.H. Freeman and Co. San Francisco (1980). The estimrated Tm for each of the three proteins is listed in Table 2.

Table 2 Estimated Melting Temeratures Protein Tm (OC) native KGF 54.0 55.0 C(1,15)S 55.0 AN23 56.6 C(l,l5)S/R(144)Q 62.5 AN23 /R144Q 63.0 C 15) S/R (144) E 63. 'As these results show, C(l,15)S and AN15 have a 1 0 C increase in the Tm as compared with native KGF.

The AN23 has an additional degree increase in Tm.

However, the substitution of R144Q to C(1,15)s/R(144)Q or AN23 add.s a greater than 6VC increase in Tm and more than 7*C as cmpared with native KGF. Moreover, C(1,15)S/R(144)E is greater than 9*C more stable than native KGF.

2 The acid stabilities of C(1,15)S/R(144)Q and C(1,15)S/R(144)E were also compared to that of native KGF, by adjusting D-PBS to different pH values by adding concentrated HCl or NaOH. Approximately 2.35 mL of 0-PBS at different PH values was mixed with 100 pL of 2.45 mg/mtL KGF protein in a. quartz cell. -These samples were thermally unfolded at a rate of 50°C/hr and monitored by CD at 230 nm. Figure 28 shows the Tm as a function ofpH for native KGF, C(1,15)S, C(1,15)S/R(144)Q and C(1,15)S/R(144)E. In the pH range tested, the C(1,15)S, C(1,15)S/R(144)Q and C(1,15)S/R(144)E always have a higher Tm than the native KGF.

In vitro Biological Activity In vitro mitogenic activity of C(1,15)S, AN15, AN23, AN23/R(144)Q, C(1,15)S/R(144)Q and C(1,15)S/R(144)E was also determined as a function of protein concentration and the half-maximal concentrations by measurement of 3 H]-thymidine 9 uptake by Balb/MK cells (according to the methods of Rubin et al. (1989), supra).

9 10 Generally, the concentrations of each of the KGF analogs relative to a known standard native KGF was determined using an in vitro biological assay. Each KGF analog was then diluted and assayed for biological activity using a Balb/MK mitogenic assay. The samples were first diluted in a bioasssay medium consisting of 50% customer-made Eagle's MEM, 50% customer-made F12, 5 pg/ml transferrin, 5 ng/ml sodium selenite, 0.0005% HSA and 0.005% Tween 20. KGF samples were then added into Falcon Primeria 96-well plates seeded with Balb/MK cells. Incorporation of 3 H]-Thymidine during DNA synthesis was measured and converted to input native KGF concentration by comparison to a native KGF standard curve. The results are presented in Figures 29 to 34. As seen in the Figures, the tested KGF analogs described in Figures 28 to 33 have comparable activity to native KGF.

48 Production in Mamalan Cell. Cul ture This example describes the expression, isolati.on,:and characterization of two biologically active recombinant KG? (r~dF) 'f-ozs Produced in a mnammhalian expression system.

Th e h~.iazi KG? gene was isolated by pcR.

amplification of CDNTA made from norma) dermal huiman fibroblast cells (Clonetec, Inc., San Diego,

CA).

Following the making of CDNA by reverse transcriptase, PCR was used to amplify the KG? gene. OLIGO#25 and OLIGO#26 were used to amplify the gene Out of the cDNA, and OLZGO#27 and OLIGO#28 were used to place Himdri and EgIli restriction sites at the fragment ends by a second FCR amplification, as set forth in Figures lA and 1B.

*a *6

U

U U

U.

U

U.

U

U

U

*0*U S U 4

U

S C

U

OLZGMS2 (SEQ ID NO:g9): OLZGO,26 (SEQ =D OLIrG0#27 (SEQ =D NO:71): 20 OLIGO#28 (SEQ =D NO:72): S -TT'AGTTATTCCATAW-~ 3

S

SACAJGCT=ACAATTAGTAGGA.

3 SAC~-TTAGTTGCTW 3 'Following cloning and DNA sequence confimtion, the KGF gene ML& was then used.

Amplification was'effected using OLIGO#29 and 0O.LIGOU 0.

OLzGOe29 (SEQ MD NO:73): 'CGG1TCACCACC'-LATGGATACWAlrr- (SEQ IDNO:74):

S.GCGTGACCTAAAATCWCATAQG_~,

3 The sense primer, OLIGO#29, included an Xbal site and a consensus Kozak translation sequence CCACC-3 1) upstream of the start codon, ATG. The antisense Primer, OLIG0#3O, included a Sall 'cloning site and an additional stop codon.. Aft er 18 cycles of PCR amplification (30 sec. denaturation at 94'C, 40 sec.

OFR~~K

49 annealing at 55'C, and 40 sec. elongation at 72'C), the product was digested with XbaI and Sail and ligated with a similarly digested DNA of pDSRa2 (according to the methods of Bourdrel et al. (1993), Protein Exp. Purif., A:130-140 and Lu et al. (1992), Arch. Biochem.

Biophys., 29:150-158). This resulted in plasmid KGF/pDSRa2 which placed the human KGF gene between the early promoter and the a-FSH polyadenylation sequences. Two clones were picked and DNA sequence analysis confirmed construction of the desired vector.

Two micrograms of KGF/pDSRa2 DNA were then linearized with PvuI. Chinese hamster ovary (CHO) cells, seeded the day before at 0.8 x 106 cells/60 mm culture dish, were then transfected with the treated DNA 15 using a standard calcium phosphate precipitation method (Bourdrel et al., supra). Two weeks later, individual colonies were picked and transferred into 24-well plates. The conditioned media was considered serum free when the cells reached confluency and aliquots thereof 20 were analyzed by Western blotting using a polyclonal rabbit antiserum reactive against E. coli-expressed human KGF.

Westerns were performed by running samples through 12.5% SDS polyacrylamide gels, followed by electroblotting for 1 hr. at 400 mA onto nitrocellulose membranes using a semidry transfer apparatus (Hoefer Scientific Instruments, San Francisco, CA). 20 mM Tris, 150 mM glycine, 20% methanol served as the transfer buffer. The nitrocellulose sheets were blocked by incubation with 10% normal goat serum in PBS. Rabbit anti-serum raised against E. coli-derived KGF was used as primary antibody. For use, it was diluted 1/10,000 in 1% normal goat serum in PBS and incubated with the blocked nitrocellulose sheets for 12 hr. at room temperature, after which excess antibody was removed by three 30 min. washes in PBS. The nitrocellulose 50 membranes were then incubated in 100 mL of 1% normal goat serum in PBS containing Vectastain T m biotinylated goat anti-rabbit IgG (secondary antibody, Vector Labs, Burlingame, CA) for 30 minutes at room temperature.

After three 10-minute washes in PBS, a 3 0-minute room temperature incubation was performed in a 100 mL solution of 1% normal goat serum containing streptavidin and biotinylated peroxidase, prepared according to manufacturer's directions (Vector Labs). Following three washes in PBS, KGF cross-reactive material was visualized by incubation in a mixture of 60 pL of H20 2 in 100 mL of PBS and 50 mg of 4 chloronapthol in 20 mL of methanol. The reaction was stopped by rinsing in water after 10 minutes.

Analysis of the blots revealed that the KGFspecific antibody associated with three distinct protein bands, two being closely related with molecular weights of about 25-29 kDa and one with an estimated molecular weight of about 17 kDa, as compared to the expected molecular weight of approximately 18.8 of the 163 amino acid mature protein. Additionally, several high-expressing clones secreting more than 2.0 mg of rKGF per liter, as judged by Western analysis, were selected and expanded into roller bottles (according to the method of Lu et al., supra) to generate large volumes of serum-free conditioned medium for purification of KGF by cationic exchange chromatography and gel filtration, as set forth below.

KGF from 3 L of serum-free conditioned medium was purified applying the medium directly to a cation exchange column (5 x 24 cm) packed with 450 ML of sulfoethyl a column of S-Sepharose Fast Flow (Pharmacia) pre-equilibrated with 20 mM sodium phosphate, pH After washing with five column volumes of 20 mM sodium phosphate, 0.2 M NaCl, pH 7.5, rKGF was eluted using a volume linear gradient of 0.2 to- 1.0 M NaCl in 51 mM sodium phosphate, pH 7.5. 50 mL fractions were collected with continuous

A

28 O monitoring. KGF protein was detected by analyzing aliquots of each fraction by SDS-PAGE. SDS-PAGE was performed on an electrophoresis system (Novex, San Diego, CA) using precast 14% Trisglycine precast gels (according to the method of Laemmli (1970) Nature, 222:680-685). Samples were mixed with non-reducing SDS sample buffer without heating before loading. The proteins were detected by either Coomassie blue or silver staining. Two late-eluting peaks were seen to contain protein bands corresponding to the 25-29 kDa and 17 kDa bands detected by Western blot. The fractions containing each of these peaks were separately concentrated to a volume of less than 1.0 mL and 15 subjected to gel filtration.

The gel filtrations employed columns of Superdex-75" resin (HR 10/30, Pharmacia) preequilibrated with PBS, pH 7.2, and calibrated with the following known molecular weight standards (BioRad, San 20 Francisco, CA): thyroglobulin (670 kDa), g-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B-12 (1.4 kDa). These purification steps resulted in an approximate 2000-fold purification of 0 rKGF, specifically including a 17 kDa and a 30 kDa material, as estimated by silver staining.

In the instance of the higher molecular weight material, rKGF eluted as a major symmetrical peak (by A 2 8 0 which was called KGF-a. Upon SDS-PAGE analysis of a lesser amount of this material, 3 gg/lane versus 6 gg/lane, two bands with a 1-2 kDa molecular weight differeice were resolved. In the instance of the lower molecular weight material, termed KGF-b, gel filtration resulted in a protein preparation having the expected mobility. For both KGF-a and KGF-b, the overall yield after purification was approximately 30-40%.

52 Amino acid sequences from KGF-a and KGF-b were also analyzed. These analyses were performed on an automatic sequencer (Model 477A or 470A, Applied Biosystems, Inc., Foster City, CA) equipped with a Model 120A on-line PTH-amino acid analyzer and a Model 900A data collection system (according to the method of Lu et al. (1991), J. Biol. Chem. ,266: 8102-8107). Edman sequence analysis of KGF-a revealed a major N-terminal sequence of X1-N-D-M-T-P-E-Q-M-A-T-N-V-X 2

-X

3 [SEQ ID 10 NO:75]. A minor sequence starting from the third Nterminal amino acid, aspartic acid, was also present in 1.6% of the total sequenceable protein. X 1

X

2 and X 3 were the unassigned due to the absence of phenylthiohydantoinyl (PHT) amino acid signals during sequence analysis. An N-terminal amino acid sequence of KGF predicted from cDMA sequence indicates that X 1 and X 3 are Cys residues and X 2 is asparagine. The absence of Xi and X 3 indicates that these cysteines may form disulfide bridges. On the basis of the consensus N-linked glycosylation sequence Asn-X-Ser, the absence of the predicted Asn residue corresponding to X 2 indicates that it is a potential N-linked glycosylation site.

0 Interestingly, N-terminal sequence analysis of KGF-b revealed an N-terminal amino acid sequence of S-Y-D-Y-M-E-G-G-D-I-R-V- (SEQ ID NO:76), indicating that it is an N-terminally truncated form of KGF that has been proteolytically cleaved at the Arg 2 3 -Ser 2 4 peptide bond.

To further characterize purified KGF-a and KGF-b, the protein was subjected to glycosidases (neuraminidase, O-glycanase, and/or N-glycanase), using known techniques (Sasaki et al. (1987), J. Biol. Chem., 2ai:12059-12076; Takeuchi et al. (1988), J. Biol. Chem., 26i:3657-3663; Zsebo et al. (1990), Cell, 1:195-201).

These data indicate that KGF-a contains N- and O-linked carbohydrates, although the lower molecular weight form 53 of KGF-a probably contains only N-linked sugar.

Glycosidase treatment did not cause molecular weight reduction for KGF-b, indicating that the :moleicule is unglycosylated.

The glycosylation pattern of KG?-a was -further characterized by mass spectroscopy of the endoproteinase Glu-C-generated peptides described above. Elucidation of carbohydrate structure of glycopeptides by the stepped orifice method of mass spectrometric ;analysis has been successfully applied to Other proteins (Huddleston et al. (1993), Anal. Cbem., :877-884; Carr et al. (1993), Prot. Scl., 2:183-196).* As confirmned by 0 the isolation of a non-glycosylated peptide, Thr 22 seems to be partially glycosylated. Similar mass :15 spectrometric analysis of Asn 1 4 suggested

*LOS

Pi microheterogeneity in glycosylation, with bi, tri and tetra-antennary structures with varying degrees of s ialylation.

.Table 3A,'sua izes the KG? concentration to 20 stimulate 3 HJ -thymidine incorporation of keratinocytes; S. at half-maxima rate (according to the method of Rubin et al. (1989), -Supra) interaction with the KG? receptor was examined using isolated KG? receptor 0 Membrane Preparations prepared from Balb/MK mouse epidermzal keratinocytes (by the procedure described by Hassague (1983) Biol. Chem., =.~:13614-13620).

Specifically, various forms of KG? were diluted with MM Tris-HC PH 7.5, containing 0.2% bovine seru.m albumin so as to range in concentration from 0. 8 ng to 100 ng per 50 IL. They were individually- incubated with the membrane preparation (75 ng/mL) and 1 2 5 1-labeled

E.

coi-derived KG? (1.5 Receptor binding and competition experiments were performed at VC for 16 hr., after which time samples were taken, centrifuged, and washed twice with the above diluent buf fer to remove unb,, ound and non-specifically bound, labeled KG?.

-54 Samples were then counted f or the remaining radioactivity. Competition curves for receptor binding between KGF samples and labeled KGF were constructed by plotting percent uncompetition versus concentrations of each KG? sample. Table 3B suxnxarizes the KG? concentration needed to achieve 60% uncompetition.

against the labeled E. coli derived KG?, expressed as ng/mL.

10 Table 3A KG? concentration to stimulate H-hm incornoration-of keratinocvtes at half-Maximal rate is Forms nr/nIL E. coli KGF KGF-a KXGF-b Table 3B KG? concentration- to corroete receptor binding with T1 2 5 -labeledg KG? at 60% unconmetit'o rte Forms ngi/mrL E. coi KG? 65.8 KGF-a 93.5 KGF-b 89.1 As shown in Table 3A, KGF-a and KGF-b stimulate comparable (3H] -thymidine incorporation, with the half -maximal rate being stimulated by approximately ng/ml of either analog. Thus, the truncation does not reduce biological activity of the molecule.

However, the two analogs have approximately 3-fold lower ac tivity than the E. coli-derived, full-length KGF. As shown in Table 3B, radioreceptor assay uncompetition 55 experiments indicated that E. coli-derived KGF, KGF-a, and KGF-b have similar receptor binding activity.

dMie: In Vivo Biological Assay of KGF Polypeptides Produced in E. coli and Mammalian Cell Culture A single subcutaneous dose of KGF has been shown to result in a dose-dependent rise in serum cholesterol in mice within 24 hours. Native KGF, KGF-a, C(1,15)S, AN15 and AN23 were also evaluated for the ~ability to raise the serum cholesterol level in a dosedependent manner.

Each treatment group contained five female ".iBalb/c mice (18-20 gms) obtained from CRL. The protein was diluted with 0.9% saline to achieve a final injection volume of 100 gl/mouse. Each mouse was administered a single subcutaneous injection, at the following doses: oo oo 56

I

GOoUD0 Treat-m, 4 i Native KGF Native KGF Native KGF Native KGF Native KGF C (1 is) S C 15) S C 15) S C is) S C (1 1) S AMis AMiS

ANIS

AN2 3 A5N2 3 A5N23 AN2 3 KGF-a KGF-a KGF-a KGF-a Saline control I Doug(ag/ka) 0.1 0.25 1 0.2.

0.2S 1 0.25 1 0.1 1 0.01 0.05 0.21

I

I Twenty-four hours after injection, the mice were sacrificed and bled via cardiac puncture. Blood samples were processed for the determination of serum 57 As shown in Figure 35, each tested KGF analog was found to raise serum cholesterol in a dose dependent manner. Also, there was no apparent difference in bioactivity between any of the tested KGF analogs.

In Vivo Model of Diabetes Chemically-induced diabetes mellitus models in various animal species have been classically used to study the disease and its treatment. Streptozotocin induces diabetes in the mouse, rat, hamster, dog, and monkey although studies in rats and mice are utilized most. Junod et al., Proc. Soc. Exp. Pio. Med. 126:210- 205 (1967); Rerup, Pharm. Rev. 22:485-518 .(1970); Rossini et al., P.N.A.S. 74:2485-2489 (1977); and Ar'Rajab and Ahren, Pancreas 8:50-57 (1993). In rats, doses of streptozotocin from 45 to 70 mg/kg as a single intravenous dose induce stable disease. Doses below mg/kg induce a transient disease state which is reversible. Within one day of streptozotocin injection, the hyperglycemic state is induced. Blood insulin levels remain essentially unchanged compared with normal rats; ooo however, the total content of insulin and C-peptide in the pancreas is severely decreased. Rats manifest the classic signs and symptoms of diabetes in humans: increased blood glucose levels (hyperglycemia), glucose in the urine (glucosuria), increased thirst (polydipsia), increased urination (polyuria), increased appetite (hyperphagia).

The studies described in this disclosure were carried out with the streptozotocin-induced diabetes model in Sprague-Dawley rats. Male rats weighing 200 260 grams at study initiation were used. Diabetes was induced by a single intravenous injection of streptozotocin at 50 mg of streptozotocin in sodium citrate buffer per kg of body weight. Non-diabetic 58 control rats received a single intravenous injection of sodium citrate buffer for control purposes. KGF was administered daily as a subcutaneous injection. The KGF dose was 3 or 5 mg/kg/day, depending upon the experiment.

In the first experiment, KGF therapy was initiated two days before diabetes, was induced and continued after the induction of diabetes for a total of eight injections.

In the second and third experiments, KGF therapy administered subcutaneously was initiated one day after 10 the induction of diabetes with streptozotocin. In the fourth experiment, a 7 day course of KGF therapy was initiated 7 days after streptozotocin treatment and the animals were then followed for an additional 12 weeks.

In all experiments, except for the fourth experiment, blood glucose levels, urine glucose levels and urine Svolume were used as end points for analysis.

Additionally, water intake, urine C-peptide levels, or total pancreatic insulin and C-peptide content were measured in some experiments. In the fourth experiment, the only assessed endpoint was blood glucose.

Because a large fraction of insulin is removed from the circulation by the liver, measurement of peripheral insulin concentrations reflect post-hepatic metabolism events rather than insulin secretion from the pancreas.

Therefore, measurements of C-peptide are often made and used as a peripheral marker of insulin secretion.

C-

peptide is produced from the processing of pro-insulin to insulin. Insulin and C-peptide are secreted from the beta cells in equimolar amounts, and only a small amount of C-peptide is extracted by the liver.

This study investigated the effect of rKGF on streptozotocin-induced diabetes in Sprague-Dawley rats.

On day 0, groups of rats were exposed to either 45 or mg/kg streptozotocin (STZ). Following these treatments, non-fasting blood glucose levels were monitored daily to assess the severity of the islet injury. On day 5, the i 59 STZ-treated animals were placed into one of two groups depending on the magnitude of hyperglycemia.

The dividing point was set at a blood glucose level of 300 mg/dl. A group of non-STZ-treated animals served as controls. On day 7, 10 animals from each hyperglycemic group were given MN23 (3 mg/kg/day) or PBS by subcutaneous injection for 7 days. Blood glucose levels were then monitored daily, every other day, or weekly and are set forth in Figure 50. Note that STZ-treated animals from both groups receiving AN23 had significant declines in blood glucose during the AN23 dosing period.

Importantly, the mean blood glucose drop experienced by 0 the STZ-treated animals from the <300 mg/dl starting blood glucose group stabilized at about 150 mg/dl whereas 15 the blood glucose drop seen in the >300 mg/dl starting blood glucose group was only transient. Note that the day scale is non-linear.

While the present invention has been described above both generally and in terms of preferred 20 embodiments, it is understood that other variations and modifications will occur to those skilled in the art in light of the description above. O• o•

Claims (13)

1. A biologically active analog of native keratinocyte growth factor (KGF), said native KGF having the amino acid sequence of SEQ ID NO.2, wherein the analog comprises a modification of at least the cysteine at position 32 and the cysteine at position 46 of the amino acid sequence of the native KGF, which modification is either a deletion or substitution, with the proviso that: the analog is not a KGF comprising a deletion of amino acids 1 to 58 of the native KGF; and the analog is not a KGF protein consisting of amino acids 55 to 194 of the 10 native KGF.

2. The analog according to Claim 1, wherein the cysteine residue at amino acid S> position 32 of SEQ ID NO:2 and the cysteine residue at amino acid position 46 of SEQ ID NO:2 are deleted.

3. The analog according to Claim 1, wherein amino acids 32-55 of SEQ ID *0 15 NO:2 are deleted.

4. The analog according to Claim 1, wherein the cysteine residue at amino acid position 32 of SEQ ID NO:2 is deleted and the cysteine residue at amino acid position 46 of SEQ ID NO:2 is substituted with another amino acid.

5. The analog according to Claim 1, wherein up to the first fourteen N-terminal amino acids are deleted and the cysteine residue at amino acid position 46 of SEQ ID NO:2 is substituted with another amino acid.

6. The analog according to Claim 1, wherein the cysteine residue at amino acid position 32 of SEQ ID NO:2 and the cysteine residue at amino acid position 46 of SEQ ID NO:2 are substituted with another amino acid.

7. The analog according to any one of Claims 4 to 6, wherein an amino acid residue selected from alanine, leucine or serine is substituted for a cysteine residue. -61-

8. The analog according to Claim 7, wherein a serine residue is substituted for a cysteine residue.

9. The analog according to any one of Claims 1 to 8 further comprising a charge-change substitution at an amino acid position selected from the arginine residue at amino acid position 72 of SEQ ID NO:2, the glutamic acid residue at amino acid position 74 of SEQ ID NO:2, the lysine residue at amino acid position 86 of SEQ ID NO:2, the lysine residue at amino acid position 126 of SEQ ID NO:2, the asparagine residue at amino acid position 168 of SEQ ID NO:2, the glutamic acid residue at amino acid position 169 of SEQ ID NO:2, the lysine residue at amino acid position 170 of SEQ ID NO:2, the arginine residue at amino acid position 175 of SEQ ID NO:2, the lysine residue at amino acid position 178 of SEQ ID NO:2, the glutamine residue at amino acid position 183 of SEQ ID NO:2, the lysine residue at amino acid position 184 of SEQ ID NO:2, or the threonine residue at amino acid position 185 of SEQ ID NO:2.

10. The analog according to any one of Claims 1 to 9, further comprising at 15 least one amino acid in the loop-forming sequence of amino acid residues at positions Asnl 4 6 -Thrl50 of SEQ ID NO:2 being replaced by a residue of a different amino acid having a higher loop-forming potential.

11. The analog according to any one of Claims 9 to 10, wherein amino acids

32-54 of SEQ ID NO:2 are deleted. 12. The analog according to Claim 1, wherein the analog is C(1,15)S (which corresponds to SEQ ID NO:32, with the initial methionine residue being considered residue C(1,15,40)S (which corresponds to SEQ ID NO:78, with the initial methionine residue being considered residue C(1,15,102)S (which corresponds to SEQ ID NO:80, with the initial methionine residue being considered residue -62- residue being considered residue AN15 (SEQ ID NO:42, with the initial methionine residue being considered residue AN16 (which corresponds to SEQ ID NO:44, with the initial methionine residue being considered residue AN17 (which corresponds to SEQ ID NO:46, with the initial methionine residue being considered residue AN18 (which corresponds to SEQ ID NO:48, with the initial methionine residue being considered residue AN19 (which corresponds to SEQ ID NO:50, with the initial methionine residue being considered residue AN20 (which corresponds to SEQ ID NO:52, with the initial methionine residue being considered residue AN21 (which corresponds to SEQ ID NO:54, with the initial methionine residue being considered S: 10 residue AN22 (which corresponds to SEQ ID NO:56, with the initial methionine residue being considered residue AN24 (which corresponds to SEQ ID NO:60, with the initial methionine residue being considered residue AN3/C(15)S (which corresponds to SEQ ID NO:34, with the initial methionine residue being considered residue AN3/C(15)- (which corresponds to SEQ ID NO:36, with the initial 15 methionine residue being considered residue AN8/C(15)S (which corresponds to SEQ ID NO:38, with the initial methionine residue being considered residue AN8/C(15)- (which corresponds to SEQ ID NO:40, with the initial methionine residue being considered residue C(1,15)S/R(144)E (which corresponds to SEQ ID NO:62, with the initial methionine residue being considered residue C(1,15)S/R(144)Q (which corresponds to SEQ ID NO:64, with the initial methionine residue being considered residue AN23/H(116)G (which corresponds to amino acids 54-194 of SEQ ID NO:2), with the histidine residue at amino acid position 147 being substituted with a glycine; AN23/N(137)E (which corresponds to SEQ ID NO:84, with the initial methionine residue being considered residue AN23/K(139)E (which corresponds to 2 22135-00.DOC

22135-OO.DOC -63- SEQ ID NO:86, with the initial methionine residue being considered residue AN23/K(139)Q (which corresponds to SEQ ID NO:88, with the initial methionine residue being considered residue AN23/R(144)A (which corresponds to SEQ ID with the initial methionine residue being considered residue AN23/R(144)E (which corresponds to SEQ ID NO:92, with the initial methionine residue being considered residue AN23/R(144)L (which corresponds to SEQ ID NO:94, with the initial methionine residue being considered residue AN23/K(147)E (which corresponds to SEQ ID NO:96, with the initial methionine residue being considered residue AN23/K(147)Q (which corresponds to SEQ ID NO:98, with the initial 10 methionine residue being considered residue AN23/N(153)E (which corresponds to SEQ ID NO:100, with the initial methionine residue being considered residue AN23/NK(153)Q (which corresponds to SEQ ID NO:102, with the initial methionine residue being considered residue AN23/Q(152)E/K(153)E (which corresponds to SEQ ID NO: 104, with the initial methionine residue being considered residue or 15 AN23/R(144)Q (which corresponds to SEQ ID NO:66, with the initial methionine residue being considered residue 13. The analog according to claim 12, wherein the initial methionine of any one of SEQ ID NOs: 32, 78, 80, 82, 42, 44, 46, 48, 50, 52, 54, 56, 60, 34, 36, 38, 40, 62, 64, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104 or 66 is absent. 14. The analog according to Claim 12 or Claim 13, wherein said analog is AN16 (which corresponds to SEQ ID NO:44, with the initial methionine residue being considered residue The analog according to claim 14, wherein the initial methionine of SEQ S.ST± ID NO:44 is absent. -22135-00.DOC -64- 16. The analog according to any one of Claims 1 to 15, wherein said analog has a signal sequence or an amino-terminal methionine residue. 17. The analog according to Claim 16 wherein said signal sequence is amino acids 1-31 of SEQ ID NO:2. 18. The analog according to any one of Claims 1 to 17, wherein said analog is covalently attached to a chemical moiety. 19. The analog according to Claim 18, wherein said chemical moiety is polyethylene glycol. 20. An analog of native keratinocyte growth factor (which corresponds to amino acids 32-194 of SEQ ID NO:2, with or without a signal sequence), termed "KGF", wherein said analog is AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue and wherein the analog is covalently attached to a chemical moiety. 21. The analog according to Claim 20,wherein the initial methionine of SEQ 15 ID NO:58 is absent. 22. The analog according to Claim 20 or Claim 21, wherein said chemical moiety is polyethylene glycol. 23. The analog according to any one of Claims 1 to 22, wherein said analog is lyophilized. 24. A pharmaceutical formulation comprising a therapeutically effective amount of an analog of KGF according to any one of Claims 1 to 23 and a pharmaceutically acceptable carrier. A recombinant nucleic acid molecule encoding an analog according to any one of Claims 1 to 17. 22135-OO.DOC 26. A biologically functional vector comprising a nucleic acid molecule according to Claim 27. A prokaryotic or eukaryotic host cell containing a nucleic acid molecule according to Claim 25 or a biologically functional vector according to Claim 26. 28. A prokaryotic host cell according to Claim 27 that is E. coli. 29. A eukaryotic host cell according to Claim 27 that is a mammalian cell. A eukaryotic host cell according to Claim 29, wherein said cell is a Chinese hamster ovary cell. 31. A nucleic acid molecule which is SEQ ID NO:57. 32. A process for the production of an analog of KGF, the process comprising growing under suitable nutrient conditions a host cell according to any one of Claims 27 to 30 in a manner allowing expression of the encoded analog, and isolating the analog so produced. 33. A use of an effective amount of the analog of KGF according to any one 15 of Claims 1 to 23 for the production of a medicament for stimulating production of non- fibroblast epithelial cells. 34. The use according to Claim 33, wherein said non-fibroblast epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory and gastrointestinal tracts, corneal cells or tympanic epithelial cells. A use of an effective amount of the analog of KGF according to any one of Claims 1 to 23 for the production of a medicament for stimulating production of non- fibroblast epithelial cells in a patient for the prevention or treatment of a condition, wherein said condition is selected from bums and other partial and full-thickness n 1 injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; -66- progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; corneal abrasion; progressive gum disease; ear drum damage or diabetes mellitus. 36. A method of stimulating the production of non-fibroblast epithelial cells comprising the administration to a subject of an effective amount of an analog of KGF according to any one of Claims 1 to 23, or a pharmaceutical composition according to S* 10 Claim 24. 37. The method of Claim 36, wherein the non-fibroblast epithelial cells are stimulated in a patient in need thereof. 38. The method of Claim 37, wherein said non-fibroblast epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the 15 respiratory and gastrointestinal tracts, coreal cells or tympanic epithelial cells. 39. A method for the prevention or treatment of a condition in a patient comprising the administration of an effective amount of an analog of KGF, according to any one of Claims 1 to 23, or a pharmaceutical formulation according to Claim 24, wherein said patient has a condition selected from burs and other partial and full- thickness injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; 22135-00.DOC -67- toxic insults to the liver; coreal abrasion; progressive gum disease; ear drum damage or diabetes mellitus. A use of an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue for the production of a medicament for stimulating production of non-fibroblast epithelial cells in a patient in need thereof, wherein the non-fibroblast epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells. 41. A method of stimulating the production of non-fibroblast epithelial cells S10 comprising the administration to a subject of an effective amount of AN23 (which go corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue or a pharmaceutical composition thereof, wherein the non-fibroblast *oo* epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells. 15 42. A use of an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue for the production of a medicament for stimulating production of non-fibroblast epithelial cells in a patient for the prevention or treatment of a condition, wherein said condition is selected from bums and other partial and full-thickness injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; toxic insults to the liver; progressive gum disease; ear drum damage or diabetes mellitus. 22135-00.DOC -68- 43. A method for the prevention or treatment of a condition in a patient comprising the administration of an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue wherein said patient has a condition selected from burns and other partial and full- thickness injuries; epidermolysis bullosa; chemotherapy-induced alopecia; male-pattern baldness; progressive loss of hair in men and women; gastric and duodenal ulcers; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; gut toxicity in radiation and chemotherapy treatment regimes; hyaline membrane disease; acute or chronic lung damage; hepatic cirrhosis; fulminant liver failure; acute viral hepatitis; 10 toxic insults to the liver; progressive gum disease; ear drum damage or diabetes mellitus. S44. The use according to Claim 40 or Claim 42, wherein the initial methionine of SEQ ID NO:58 is absent. A method of stimulating the production of non-fibroblast epithelial cells comprising contacting said cells with an effective amount of AN23 (which corresponds to SEQ ID NO:58, with the initial methionine residue being considered residue or a pharmaceutical composition thereof, wherein the non-fibroblast epithelial cells are selected from adnexal structures, pancreatic cells, liver cells, mucosal epithelium in the respiratory tract or tympanic epithelial cells. 46. A method according to any one of Claims 41, 43 or 45, wherein the initial methionine of SEQ ID NO:58 is absent. 47. The method according to any one of Claims 36 to 39, 41, 43 or wherein said analog of KGF is administered via IV, IT, IM, SC, or IP routes. 48. A kit comprising an analog of KGF according to any one of Claims 1 to 23, or a pharmaceutical formulation according to Claim 24. 22135-00.DOC -69- 49. A method of stimulating the production of non-fibroblast epithelial cells comprising contacting said cells with an effective amount of an analog of KGF according to any one of Claims 1 to 23, or a pharmaceutical composition according to Claim 24. 50. An analog of native keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. 51. A pharmaceutical formulation comprising an analog of native keratinocyte growth factor, substantially as herein described with reference to any one of o S the examples but excluding comparative examples. 52. A recombinant nucleic acid molecule encoding an analog of native keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. •53. A biologically functional vector comprising a recombinant nucleic acid V V 15 molecule encoding an analog of native keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. 54. A prokaryotic or eukaryotic host cell containing a recombinant nucleic acid molecule encoding an analog of native keratinocyte growth factor or a biologically functional vector comprising a recombinant nucleic acid molecule encoding an analog of native keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. A process for the production of an analog of keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding TRd> 25 comparative examples. 22135-OO.DOC 56. A use of an effective amount of an analog of keratinocyte growth factor for the production of a medicament, substantially as herein described with reference to any one of the examples but excluding comparative examples. 57. A method of stimulating the production of non-fibroblast epithelial cells comprising the administration to a subject of an effective amount of an analog of keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. S58. A method for the prevention or treatment ofa condition in a patient comprising administering an analog ofkeratinocyte growth factor, substantially as herein 9. 9 *o 9• described with reference to any one of the examples but excluding comparative examples. 59. A use of an effective amount of AN23 for the production of a 9 medicament, substantially as herein described with reference to any one of the examples S but excluding comparative examples. 9999 15 60. A method of stimulating the production of non-fibroblast epithelial cells *9•o 9• comprising the administration to a subject of an effective amount of AN23, substantially as herein described with reference to any one of the examples but excluding comparative examples. 61. A method for the prevention or treatment of a condition in a patient comprising the administration of an effective amount of AN23, substantially as herein described with reference to any one of the examples but excluding comparative examples. 62. A method of stimulating the production of non-fibroblast epithelial cells comprising contacting said cells with an effective amount of AN23, substantially as 22135-OO.DOC -71 herein described with reference to any one of the examples but excluding comparative examples. 63. A method of stimulating the production of non-fibroblast epithelial cells comprising contacting said cells with an effective amount of an analog of keratinocyte growth factor, substantially as herein described with reference to any one of the examples but excluding comparative examples. 64. A kit comprising an analog ofkeratinocyte growth factor or a pharmaceutical formulation comprising an analog of keratinocyte growth factor, •substantially as herein described with reference to any one of the examples but excluding S10 comparative examples. DATED this 12' day September of 2001 ¢AMGEN INC 15 Attorney: IVAN A. RAJKOVIC SFellow Institute of Patent Attorneys of Australia of BALDWIN SHELSTON WATERS S 22135-00.DOC